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AMP   Anti-microbial peptide 
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ASC   Apoptosis-associated speck-like protein containing a CARD 
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BFP   Blue fluorescent protein 
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II Abstract 
1 English 
The importance of the microbiota on health and immune homeostasis is widely accepted 
and many studies are currently dissecting the interaction between the microbiota and our body. 
However, most of these studies are focusing on bacteria alone, although viruses, fungi and 
archaea were also found in this microbial community. Recent studies showed that archaea are 
present at nearly every part of the body but their contribution to health and disease is not 
understood. The gut-associated methanogenic archaeon Methanosphaera stadtmanae induces 
inflammatory responses, however, the mechanism how this archaeon is sensed by the immune 
system has not been evaluated until now. In contrast, another methanogenic gut inhabitant, 
Methanomassiliicoccus luminyensis, is discussed for supplementation in humans as it has the 
unique metabolic capability to degrade trimethylamines, which can be harmful for the human 
host. Yet, its immunostimulatory activities have not been investigated. This study aims (1) to 
elucidate the receptors, archaeal structures and signaling pathways that are engaged upon 
activation of human immune cells by M. stadtmanae and (2) to analyze immunological features 
of M. luminyensis in order to exclude excessive immune stimulation. 
Human monocytes, monocyte-derived dendritic cells (moDCs) as well as the monocytic 
cell line BLaER1 were used to characterize M. stadtmanae-induced cellular activation on the 
molecular level showing that this archaeon is a strong activator of the innate immune system 
capable of inflammasome activation and induction of type I interferons. Stable knockout cell 
lines were generated using CRISPR/Cas9 to specifically identify TLR7 and TLR8 as key 
receptors in recognition of M. stadtmanae. Furthermore, our data demonstrate a TLR8-
dependent activation of the NLRP3 inflammasome sharing major characteristics with the LPS-
induced alternative pathway. M. luminyensis on the other hand induces only a weak response 
in moDCs compared to M. stadtmanae, probably due to its significantly lower phagocytosis 
rate. Moreover, M. luminyensis is sensitive towards anti-microbial peptides and exhibits typical 
characteristics of a commensal gut inhabitant which supports its application as probiotic 
supplement in humans for TMA degradation. 
For the first time, this work describes specific recognition of an archaeon by human 
immune cells on the molecular level. As some studies indicate a potential connection of 
M. stadtmanae to inflammatory bowel disease and lung hypersensitivity, our findings might 
help to understand how archaea are involved in inflammatory disease progression.  
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2 Deutsch 
Die Mikrobiota des Menschen ist wichtig für dessen Gesundheit und hat großen Einfluss 
auf die Immunhomöostase. Die detaillierte Erforschung der Wechselwirkung zwischen 
Mikrobiota und menschlichem Köper ist aktuell Gegenstand vieler Studien. Häufig wird 
allerdings nur die bakterielle Vielfalt betrachtet und dabei andere Mitglieder dieser 
mikrobiellen Gemeinschaft wie Viren, Pilze und Archaeen vernachlässigt. Erst kürzlich konnte 
gezeigt werden, dass Archaeen auf allen Körperstellen zu finden sind, ihr Einfluss auf 
Gesundheit und Krankheit ist jedoch weitgehend unbekannt. Methanosphaera stadtmanae ist 
ein methanogenes Archaeon, welches im Darm beheimatet ist und inflammatorische 
Immunantworten auslösen kann. Der molekulare Mechanismus, wie M. stadtmanae vom 
Immunsystem erkannt wird, ist nicht bekannt. Im Gegensatz dazu wird der Einsatz eines 
anderen Darmarchaeons, Methanomassiliicoccus luminyensis, als Probiotikum diskutiert, da es 
die einzigarte metabolische Fähigkeit besitzt, Trimethylamin zu verstoffwechseln, welches 
gesundheitsschädliche Eigenschaften besitzt. Seine immunstimulatorische Aktivität wurde 
bisher nicht beschrieben. Ziel dieser Arbeit ist es (1) die Rezeptoren, archaeellen Strukturen 
und Signalwege zu identifizieren, die wichtig für die Erkennung von M. stadtmanae durch 
Immunzellen sind und (2) die immunologischen Eigenschaften von M. luminyensis zu 
analysieren, um übermäßige Immunantworten durch diese Spezies auszuschließen. 
Humane Monozyten, Monozyten-generierte dendritische Zellen (moDCs) sowie die 
Monozytenzelllinie BLaER1 wurden verwendet, um die durch M. stadtmanae-vermittelte 
Immunantwort zu untersuchen. Dabei wurde gezeigt, dass diese Immunantwort vor allem durch 
Aktivierung des Inflammasoms und Expression von Typ I Interferonen gekennzeichnet ist. Mit 
Hilfe von CRISPR/Cas9-generierten knockout Zelllinien konnten TLR7 und TLR8 als 
Schlüsselrezeptoren identifiziert werden. Zudem wird eine TLR8-abhängige 
Inflammasomaktivierung induziert, die Eigenschaften der LPS-abhängigen alternativen 
Aktivierung aufweist. M. luminyensis löst dagegen nur schwache Immunantworten aus, 
wahrscheinlich aufgrund seiner geringen phagozytotischen Eigenschaften. Da dieses Archaeon 
sensitiv gegenüber antimikrobiellen Peptide ist, besitzt es typische Eigenschaften eines 
kommensalen Darmbewohners, was für einen Einsatz als Probiotikum spricht.  
Zum ersten Mal konnte auf molekularer Ebene die Erkennung eines Archaeons durch 
menschliche Immunzellen beschrieben werden. Da ein Zusammenhang von M. stadtmanae mit 
chronisch entzündlichen Darmerkrankungen und Lungenhypersensitivität vermutet wird, kann 
diese Arbeit dazu beitragen, den Zusammenhang zwischen Archaeen und entzündlichen 
Erkrankungen besser zu verstehen.
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III General Introduction 
1 The Innate Immune System 
In almost every situation, each individual must cope with a high quantity of microbes 
on and in our body. Prokaryotic as well as eukaryotic microorganisms live on our skin and 
mucosal surfaces, yet, most of these organisms are commensals, which means that they benefit 
from their host (e.g., by nutrient supply) without harming it. Nevertheless, our body must also 
handle manifold pathogens, in form of bacteria and viruses but also eukaryotic microorganisms 
like protozoa, worms, and algae or even pathogenic proteins called prions. The immune system 
has evolved to defend the body from those pathogens but also from toxins and cancer cells. In 
vertebrates, the immune system has two major strands: on one hand the innate immune system, 
building the first line of defense and immunological memory, and on the other hand the adaptive 
immune system with its variable receptors. Key cells of the adaptive immune system are T and 
B lymphocytes, both named after their organ of maturation, which is the thymus (T) and the 
Bursa fabricii (B, an organ only found in birds), respectively. In mammals, B lymphocytes 
mature in the bone marrow, their main function is the humoral response through secretion of 
antibodies. T cells mediate cellular immunity as their main function, which includes activation 
of B cells and killing of virus-infected cells (1). 
Main features of the innate immune system are highly conserved as they are not 
restricted to vertebrates but can be found in plants and invertebrates (2). The innate immune 
system is based on natural barriers like epithelial cells, humoral factors like anti-microbial 
peptides (AMPs) or the complement system as well as cellular immunity (3).Various 
hematopoietic cell types belong to the innate immune system with each cell type having specific 
tasks in the immune defense. The most abundant cells of the innate immune system are the 
neutrophils (also called polymorphonuclear leukocytes: PMNs) whose main function is to enter 
sites of infection and to kill invading microorganisms through phagocytosis or granules 
containing microbicidal agents (4). Together with basophils and eosinophils they form the 
family of granulocytes. Other important innate immune cell types are mast cells, natural killer 
(NK) cells, innate lymphoid cells (ILCs) or γδ T cells. Monocytes make about 10% of the 
circulating white blood cells. They engulf microbes through phagocytosis and can recognize 
and respond to most microbes via a large receptor repertoire. Monocytes migrate from the blood 
into various tissues, where they differentiate into tissue-resident macrophages (MΦ) or 
dendritic cells (DCs) (5). MΦ and DCs are both antigen presenting cells (APCs) which means 
that they can take up foreign antigens and present them after processing on their cell surface to 
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T cells. Especially DCs can initiate an adaptive immune response as they travel to the lymph 
nodes after antigen uptake and activate naïve T cells, thereby linking the innate and the adaptive 
immune system (6, 7). Due to their capability of phagocytosis and their large receptor 
repertoire, this study mainly deals with monocytes/MΦ and DCs. 
1.1 Toll-like Receptors 
The innate immune system has a broad repertoire of receptors that specifically recognize 
microbial structures. These structures are conserved across many different microbes and include 
cell wall components, lipids and nucleic acids. Initially, these structures were termed pathogen-
associated molecular patterns (PAMPs) (8), however, as they are not only restricted to 
pathogens but rather linked to most microorganisms, they are now termed microbe-associated 
molecular patterns (MAMPs) (9). The receptors that recognize MAMPs are the pattern 
recognition receptors (PRRs). Each cell of the immune system has a specific subset of PRRs 
which is defined by the cell type and its role in the immune system. PRRs are divided into 
different subclasses of which the Toll-like receptors (TLRs) are the first-described and most 
prominent. All TLRs share a common structure with a cytosolic domain called Toll-IL-1-
resistance (TIR) domain which is important for signal transduction, a transmembrane domain, 
and an ectodomain containing leucin-rich repeats (LRRs) which forms a horseshoe-shaped 
structure. The ectodomain accounts for the ligand specificity and binding (10). In humans, there 
exist ten different TLRs, either located at the cell surface or the endosome, whereas twelve 
TLRs are known in mice (Table III-1). TLRs recognize bacterial cell wall components like 
lipopolysaccharide (LPS) or lipopeptides, proteins like flagellin or profillin or different nucleic 
acids. 
After ligand binding, TLRs form homo- or heterodimers and, subsequently, signaling 
adapter molecules such as myeloid differentiation primary-response protein 88 (MyD88) or 
TIR domain-containing adaptor protein inducing IFN-β (TRIF) are engaged. Signal 
transduction pathways of TLRs involve IL-1R-associated kinases (IRAKs) and TBF receptor-
associated factors (TRAFs), finally leading to activation and nuclear translocation of 
transcription factors. These transcription factors include, amongst others, the nuclear factor 
kappa B (NF-κB) and interferon-regulatory factors (IRFs) (11). NF-κB is an essential 
transcription factor for many pro-inflammatory cytokines, such as interleukin 6 (IL-6), 
interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). Cytokines are important 
players in the immune response as they induce an acute-phase response, increase body 
temperature and cause swelling. They recruit other immune cells like PMNs and initiate the 
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adaptive immune response (12, 13). Depending on the TLR, certain IRFs are activated and 
translocated into the nucleus. IRF3, -5 and -7 are the main factors for the induction of type I 
interferons (IFNs) including IFN-α and IFN-β. While IFN-α is predominantly expressed by 
hematopoietic cells, IFN-β can be produced by most cells of the body. IFNs protect viral-
infected cells but also non-infected neighboring cells from viral replication. They enhance 
antigen presentation and can activate the adaptive immune system (14, 15).  
 
  
Table III-1. Overview of TLRs in mice and humans. 
Name Species Ligand Location 
Adapter 
molecules 
Reference 
TLR2/TLR1 
(heterodimer) 
H, M 
diacyl 
lipopeptides 
cell surface MyD88 (16) 
TLR2/TLR6 
(heterodimer) 
H, M 
triacyl 
lipopeptides 
cell surface MyD88 (17) 
TLR3 H, M dsRNA 
endosomal 
compartment 
TRIF (18) 
TLR4 H, M LPS cell surface MyD88/TRIF (19) 
TLR5 H, M flagellin cell surface MyD88 (20) 
TLR7 H, M ssRNA 
endosomal 
compartment 
MyD88 (21) 
TLR8 H, (M*) ssRNA 
endosomal 
compartment 
MyD88 (21) 
TLR9 H, M CpG DNA 
endosomal 
compartment 
MyD88 (22) 
TLR10 H, (M**) unknown cell surface unknown (23) 
TLR11 M profillin 
endosomal 
compartment 
MyD88 (24) 
TLR12 M profillin 
endosomal 
compartment 
MyD88 (25) 
TLR13 M 
bacterial 
23S rRNA 
endosomal 
compartment 
MyD88 (26) 
H, Human; M, Mouse 
* mTLR8 was originally thought to be non-functional. It is controversially discussed if natural ligands 
for mTLR8 exist or if it has just regulatory functions (27). 
** mTLR10 only present as pseudogene. 
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1.2 Recognition of Nucleic Acids by the Innate Immune System 
As nucleic acids are conserved and basic structural components for all living organisms, 
these molecules serve as important MAMPs for the innate immune system. Therefore, 
recognition of nucleic acids greatly expands the possibility to detect foreign organisms. In 
contrast to many other MAMPs, nucleic acids are not exclusively produced by microbes but 
also by the host itself. For instance, damaged host-derived cells and tissue release nucleic acids 
that might induce an immune response. Thus, nucleic acids can additionally be classified as 
danger-associated molecular patterns (DAMPs). Although nucleic acids largely extend the 
repertoire of molecular patterns, it implicates an increased risk of autoimmunity and sterile 
inflammation if endogenous nucleic acids trigger immune responses without acute danger or 
damage. Autoimmune diseases, in which the recognition of endogenous nucleic acids is 
involved, include systemic lupus erythematosus and type I interferonopathies (28). 
Nevertheless, nucleic acid-specific receptors have been shown to play a crucial role in immune 
responses against a variety of different pathogens including bacteria, viruses and protozoa (29, 
30). 
Nucleic acid-sensing receptors are effective inducers of type I IFN responses, but they 
can also trigger secretion of pro-inflammatory cytokines like TNF-α and IL-1β dependent on 
the receptor type. In principal, PRRs that detect nucleic acids can be divided into two sub-
classes. One group includes TLRs located on endosomal and lysosomal membranes, the other 
group includes cytoplasmic receptors originated from different receptor families (Figure III-1). 
In humans, endosomal TLRs comprise TLR3 as well as TLR7-9, whereas mice additionally 
express TLR13. TLR3 recognizes dsRNA and utilizes TRIF as adaptor molecule, while signal 
transduction of TLR7-9 is dependent on MyD88. TLR7 and TLR8 both recognize ssRNA, 
TLR9 is specific for unmethylated CpG DNA (31). The most recent identified nucleic acid-
sensing TLR is TLR13 which recognizes a specific sequence in bacterial 23S rRNA (32). The 
function of all endosomal TLRs depends on a protein called UNC93 homolog B1 (UNC93B1). 
UNC93B1 interacts with the transmembrane domain of endosomal TLRs and directs them from 
the endoplasmatic reticulum (ER) to the endo(lyso-)somes (33). It was shown by Tabeta, et al. 
(34) that mice with a missense mutation in UNC93B1 (referred to as ‘3d’ mutation) no longer 
respond to ligands specific for endosomal TLRs, whereas TLRs on the surface remain 
functional. 
As TLRs exclusively recognize nucleic acids in the endosomal or lysosomal 
compartment, pathogens that successfully entered the cytosol cannot be detected efficiently by 
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Figure III-1. Overview of endosomal and cytoplasmic nucleic acid-specific receptors in humans. 
Nucleic acid-specific receptors differ in their cellular location (endosome or cytosol) and the type of nucleic acid 
that they can recognize. TLR3 and TLRs7-9 are localized in the endosome and bind to dsRNA (TLR3), ssRNA 
(TLR7 and TLR8) or unmethylated CpG DNA (TLR9). TLR3 signals via the adaptor protein TRIF, whereas 
TLR7-9 are dependent on MyD88. Activation of TLRs leads to nuclear translocation of NF-κB and a certain subset 
of IRFs to induce the production of a specific subset of cytokines and IFNs. Important cytoplasmic nucleic acid-
specific receptors are cGAS, which binds dsDNA, MDA5, which binds dsRNA, and RIG-I binding 5’-triphosphate 
RNA or short dsRNA. After engagement of cGAS by dsDNA, the intermediate cGAMP is produced from GTP 
and ATP by cGAS. cGAMP hereupon activates STING leading to production of IFNs through nuclear localization 
of IRF3 and IRF7. MDA5 and RIG-I both signal through the adaptor protein MAVS after ligand binding. MAVS 
implements the production of a certain subset of cytokines and IFNs through nuclear localization of IRF3 and 
NF-κB. (cGAS, cyclic GMP-AMP synthase; cGAMP, 2’3’-cyclic GMP-AMP; IFN, interferon; IRF, interferon 
regulatory factor; MAVS, mitochondrial antiviral signaling; MDA5, melanoma differentiation-associated gene 5; 
MyD88, myeloid differentiation primary-response protein 88; NF-κB, nuclear factor kappa B; RIG-I, retinoic acid-
inducible gene I; STING, stimulator of IFN gene; TLR, Toll-like receptor; TRIF, TIR domain-containing adaptor 
protein inducing IFN-β) 
these TLRs. To detect bacteria or viruses located in the cytosol, cells express a variety of 
different cytosolic receptors. Important cytosolic RNA receptors are Retinoic acid-inducible 
gene I (RIG-I), melanoma differentiation-associated protein 5 (MDA5) and laboratory of 
genetics and physiology 2 (LGP2, also known as DHX58), which all belong to the family of 
RIG-I-like receptors (RLRs). The ligands for RIG-I and MDA5 are 5’triphosphate RNA and 
(long) dsRNA, respectively, whereas little is known about natural ligands for LGP2. Although 
it was shown that LGP2 has the ability to bind RNA, it is thought to have rather regulatory 
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functions on RIG-I and MDA5 (35). Mitochondrial antiviral signaling protein (MAVS) is 
essential for RLR function as it aggregates on the mitochondrial membrane after RLR 
engagement and activates IRF3 to induce an antiviral response (36). Foreign and host-derived 
DNA in the cytosol is detected by cyclic GMP-AMP synthetase (cGAS) (37). Once activated 
by dsDNA, cGAS catalyzes the production of 2’,3’-cyclic GMP-AMP (cGAMP) from GTP and 
ATP. cGAMP itself acts as a second messenger and binds to stimulator of interferon genes 
(STING) which in turn utilizes IRF3 to induce expression of type I IFNs. An additional function 
of STING in human cells was recently described by Gaidt, et al. (38), who showed that STING 
can induce lysosomal cell death leading to inflammasome activation and secretion of IL-1β. 
Taken together, recognition of nucleic acids by the innate immune system plays a substantial 
role in host defense as it enables not only a potent mechanism to detect and respond to viruses 
but also to bacterial and eukaryotic pathogens.  
1.3 Inflammasomes 
Inflammasomes are large cytosolic multiprotein complexes that recognize various 
pathogenic or environmental stimuli. Once activated, the inflammasome induces autocatalytic 
cleavage of the zymogen pro-caspase-1 into its active form. An important function of caspase-1 
is the catalytical processing of the inflammatory cytokines IL-1β and IL-18 into mature, 
functional peptides (39). On the one hand, inflammasome activation supports clearance of 
microbial infection, on the other hand, if malfunctioning, inflammasome activation can lead to 
sterile inflammation and can contribute to diseases such as cancer, diabetes and Alzheimer’s 
disease (40-42). There exist several different inflammasomes in humans and mice, which differ 
in their receptor (sensor) domain. This receptor domain is either a NOD-like receptor (NLR) 
such as NLRP1, NLRP3, NLRC4, or the non-NLR AIM2. The sensor defines the stimuli that 
can activate the inflammasome e.g., NLRC4 recognizes bacterial flagellin, AIM2 binds to 
dsDNA and NLRP1 is activated by muramyl dipeptide or Bacillus anthracis lethal toxin (43-
45). In contrast, for the intensively-studied inflammasome NLRP3 there is no specific stimulus 
defined. It is reported that NLRP3 is activated by various, structurally unrelated stimuli 
including monosodium urate crystals, alum, asbestos, bacterial toxins like nigericin, 
extracellular ATP or cytoplasmic bacterial RNA. It is unlikely that NLRP3 itself can bind to all 
these different molecules and stimuli. Therefore, NLRP3 is nowadays often referred to as a 
general cellular stress sensor (46). All inflammasome receptors are linked through a protein 
called ASC (Apoptosis-associated speck-like protein containing a CARD) to pro-caspase-1 
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with exception of NLRP1 and NLRC4, which can directly interact with pro-caspase-1, 
independently of ASC (42).  
In general, three different activation pathways for NLRP3 are known, namely canonical, 
non-canonical and alternative activation. The canonical activation comprises a two-step process 
in which the first signal is needed to induce the expression of pro-IL-1β and therefore termed 
priming step (Figure III-2A). Then, a second signal is mandatory to initiate the actual 
inflammasome assembly. In case of the NLRP3 inflammasome, various endogenous and 
microbial danger signals are known that can serve as a second signal and induce inflammasome 
activation. For many of these stimuli, cellular efflux of potassium ions is of importance (47) as 
this process activates NIMA-related kinase 7 (NEK7) which was shown to be essential for IL-1β 
secretion from cells in vitro and in vivo (48-50). Still, the exact mechanism of how NEK7 
activates NLRP3 on the molecular level is unresolved. Subsequently, canonical activation of 
the NLRP3 inflammasome leads to formation of ASC specks (also called pyroptosomes), large 
macromolecular, filamentous complexes that can be visualized by electron microscopy (51, 52). 
These ASC specks are initiated by activation of NLRP3 which forms a ring-like structure and 
recruits ASC proteins that linearly polymerize. Pro-caspase-1 is then recruited to the ASC 
specks, activated and mature caspase-1 is formed by autocatalytically processing (53). Besides 
ASC speck formation, the activation of gasdermin D (GSDMD) is another characteristic feature 
of canonical inflammasome activation. Caspase-1 cleaves GSDMD which forms pores in the 
cell membrane leading to rapid efflux of intracellular components and finally to pyroptosis, a 
highly inflammatory form of programmed cell death. GSDMD only kills the cell where it was 
activated but not neighboring cells (54). As the question how processed IL-1β is secreted from 
the cells was unresolved for a long time, it was recently shown by Evavold, et al. (55) that the 
pores formed by GSDMD can serve as a channel for IL-1β to exit the cell. 
The second NLRP3 activation pathway is the non-canonical activation. In this setting, 
caspase-11 in mice (56) or caspase-4/-5 in humans (57, 58) are activated through specific 
binding of intracellular LPS. Similar to caspase-1 activation, the activation of caspase-4/-5/-11 
induces pyroptosis which causes efflux of cellular potassium, yet caspase-4/-5/-11 cannot 
trigger conversion of IL-1β itself. In fact, the potassium efflux activates the NLRP3 
inflammasome downstream of caspase-4/-5/-11, which results in activation of caspase-1 and 
secretion of IL-1β (59). 
The alternative NLRP3 inflammasome activation is the most recently described 
activation pathway. It is a species- and cell-specific pathway, so far only reported for human 
and porcine monocytes but it could not be demonstrated in murine cells. The alternative 
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activation diverges from canonical activation as it only requires a single stimulus and not a two-
step activation (Figure III-2B). The alternative pathway is induced by activation of TLR4 
through binding of LPS. Then, a TRIF-dependent signaling pathway is initiated which includes 
the molecules RIPK1, FADD and caspase-8, finally leading to NLRP3 activation. Alternative 
activation is different from canonical activation as no pyroptosis is induced, no ASC specks are 
formed and no potassium efflux is required (60). However, the role of alternative inflammation 
in infection or autoimmunity is unknown and needs to be determined. 
 
 
 
Figure III-2. Canonical and alternative activation of the NLRP3 inflammasome. 
(A) In the canonical NLRP3 inflammasome activation process, two signals are required. The first one is the 
priming step where the expression of pro-IL-1β is induced e.g., through engagement of a TLR. The second signal 
triggers the formation of the NLRP3 inflammasome complex consisting of NLRP3, ASC and pro-caspase-1 (often 
referred to as pyroptosome or ASC speck). This trigger is not a specific ligand but a rather a general stress signal 
in the cell that induces inflammasome activation. Once activated, the inflammasome turns pro-caspase-1 into its 
active form which than cleaves pro-IL-1β. This process results in activation of gasdermin D, a pore forming 
protein, inducing pyroptosis. (B) Alternative NLRP3 inflammasome activation is a process that takes place in 
human monocytes but not in murine cells. In this setting, LPS binds to TLR4 which induces expression of 
pro-IL-1β. No additional trigger is needed as TLR4 signals via TRIF-RIPK1-FADD-Caspase 8 to induce NLRP3 
inflammasome activation without pyroptosome formation. Caspase-1 is converted into its active form and cleaves 
pro-IL-1β. However, in alternative activation, no pyroptosis is induced. (Casp1, Caspase-1; Casp8, Caspase-8; 
IL-1β, Interleukin 1β; PAMP, Pathogen associated molecular pattern; TLR, Toll-like receptor) 
2 Archaea and the Human Microbiota 
2.1 Importance of the Microbiota on Health and Disease 
Given the fact that the human body is home to numerous microorganisms, at least equal 
to its own cell number (61), humans are often referred to as supra- or meta-organisms (62, 63). 
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As most human-associated microbes are considered to be commensals, others are mutualists, 
which means that the host benefits from their presence. These benefits include the synthesis of 
vitamin K, vitamin B12 and folic acid, deconjugation of bile acids or the prevention of 
colonization with pathogens (64). In the gut, microbes are separated by intestinal epithelial cells 
(IECs) from the underlying tissue, thereby forming a physical barrier (Figure III-3). The 
epithelial layer is in close connection to the immune system through the gut-associated 
lymphoid tissue (GALT). Microfold (M) cells within the epithelial cell layer take up MAMPs 
and antigens and deliver them to DCs. In addition, DCs are able to sample antigens themselves 
by stretching their dendrites between the IECs. In the Peyer’s patches and isolated lymphoid 
follicles, which are located closely to the IECs in the lamina propria, DCs can present the 
antigens to T cells and induce differentiation of B cells into immunoglobulin A(IgA)-secreting 
plasma cells. IgA is steadily translocated into to intestinal lumen. Together with AMPs, which 
are secreted by specialized IECs - the so-called Paneth cells -, both types of molecules control 
the microbial balance in the gut (65-67).  
 
 
 
Figure III-3. Schematic overview of the mucosal immune system in the gut. 
IECs form a physical barrier against microbes in the gut und protect the body from microbial infiltration. The 
immune system plays an important part in shaping the composition of the microbiota. Microbial antigens and 
MAMPs are directly sensed by IECs or sampled by M cells, thereby transferring the antigens to DCs in the Peyer’s 
patches or isolated lymphoid follicles. DC themselves can also directly take up microbes and antigens and present 
them to T and B cells. Activated B cells may differentiate into IgA-secreting plasma cells. IgA and AMPs are 
constitutively secreted into the intestinal lumen to contain homeostasis of the microbiota. (AMP, anti-microbial 
peptide; DC, dendritic cell; IEC, intestinal epithelial cell; IgA, immunoglobulin A; M cell, microfold cell; MAMP, 
microbe-associated molecular pattern) 
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The microbiota also has direct implications on the immune system as it trains the 
immune system from early life on and the immune system itself shapes the composition of the 
microbiota (68, 69). The importance of the microbiota is explicitly shown by the usage of germ-
free animals. These animals have an increased susceptibility towards pathogens caused by 
underdeveloped lymphatic tissues as well as a reduced production of mucus and AMPs. Both, 
adaptive and innate immune responses are highly compromised, demonstrating that the natural 
microbiota is essential for the development of a functional immune system (70, 71). The 
immune system senses members of the microbiota through PRRs which are mandatory to 
balance the composition of the microbiota. PRRs are not exclusively expressed by 
hematopoietic cells but also by the IECs. Their activation through MAMPs is necessary for 
steady production and secretion of AMPs and IgA, and for the epithelial barrier function in 
general (72-75). Stimulation of IECs by the natural microbiota is essential for specific cytokines 
that lead to the development of tolerogenic immune responses. If the barrier function of IECs 
is disturbed through certain genetic and environmental factors, pro-inflammatory responses 
might be induced that can break the microbial homeostasis (65). This so-called dysbiosis of the 
microbiota can have adverse effect on the host as imbalances can contribute to several diseases 
including inflammatory bowel disease (IBD) (76, 77), irritable bowel syndrome (IBS), obesity 
(78) or asthma and allergy (79). 
2.2 Archaea 
In 1977, Carl Woese claimed that archaea form an own prokaryotic domain distinct from 
bacteria, based on 16S rRNA analysis (80). Although archaea share prokaryotic features like 
the absence of intracellular compartments, the lack of a nucleus, or the circular genomic DNA 
with bacteria, other elements are closely related to eukaryotes. These include the ribosomal 
structure, DNA replication, and the translation and transcription machinery (81-83). A new view 
on the tree of life by Hug, et al. (84), which is based on ribosomal protein sequences, places 
archaea closely to eukaryotes. In addition, the recently discovered phylum of Lokiarchaeota 
strengthens the hypothesis that eukaryotes have been evolved from a common archaeal ancestor 
(85, 86). Archaea have a unique cellular structure as their cell membrane is built from ether-
linked lipids instead of ester-linked lipids that are utilized by bacteria and eukaryotes (87). 
Furthermore, the archaeal cell wall is not composed of peptidoglycan (murein) but rather 
diverse across different archaeal phylogenetic groups. For instance, surface layer (S-layer) 
proteins, pseudomurein or methanochondroitin can form the archaeal cell envelope, which are 
all unique for this domain (88).  
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Originally, archaea were regarded as extremophilic organisms that colonize habitats 
with high temperature, low pH or high salt concentrations. Over the time, archaea have also 
been discovered in rather moderate environments such as oceans, freshwater or soil (89, 90). 
The first group of archaea that were described as members of the human microbiota are the 
methanogens, originally isolated from feces of animals and later also from humans (91, 92). 
Methanogenic archaea are strictly anaerobic and utilize C1 or C2 carbon sources such as CO2 
or acetate to produce methane. As many methanogens depend on hydrogen supply, they 
frequently live in syntrophy with fermentative bacteria. The bacteria produce hydrogen which 
is used by archaea for methanogenesis and the bacteria in turn are dependent on a low hydrogen 
partial pressure to render the fermentation process thermodynamically favorable (93). 
Therefore, methanogens are thought to be an important factor in the metabolic function of the 
microbiota. This assumption is supported by the findings of Dridi, et al. (94), who showed that 
the most abundant methanogen, Methanobrevibacter smithii, is found in 96% of human guts 
and well adapted to its host, where it can make up to 10% of the anaerobic biomass (95). Other 
common methanogenic gut inhabitants are Methanosphaera stadtmanae and 
Methanomassiliicoccus luminyensis. Methanobrevibacter oralis is commonly found in the oral 
cavity (96). Yet, not all human-associated archaea are methanogens. In the gut, archaea from 
the orders Halobacteriales, Sulfolobales, Nitrosphaerales, Desulfococcales, and others have 
been discovered (97, 98). Furthermore, it was recently shown that Thaumarchaeota are present 
on the skin (99) and even in the lung, Woesearchaeota have been detected (100). However, the 
actual diversity of the human archaeome is probably vastly underestimated. Studies have shown 
that ‘universal’ 16S rRNA primers, which were thought to amplify both bacterial and archaeal 
rRNA, are highly biased towards bacteria and are not suitable for detection of most archaea in 
the microbiota (100-102). This lack of information contributes to the fact that little is known 
about the function and interaction of archaea with their host. Besides the metabolic functions 
of archaea like methane production and depletion of trimethylamine (TMA) by M. luminyensis 
(103), the actual impact of different archaeal species on health and disease remains largely 
unknown. 
2.3 Potential Disease Association of Archaea 
Although no archaeal pathogen has been identified so far, it cannot be excluded that 
they do exist. Archaea can be detected in notable abundancies on every body site and they live 
in close relationship to their host and other members of the microbiota. This fact makes a 
potential pathogenicity of certain archaeal species conceivable, yet, our current methods to 
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detect archaea in our microbiota are apparently a hindrance. Nonetheless, several studies 
suggest an involvement of archaea in different diseases. It was shown that M. smithii promotes 
obesity in gnotobiotic mouse model (95) and its number is increased in humans with obesity 
(104, 105). Furthermore, a strong correlation between the occurrence of methanogenic archaea 
and periodontal disease (106-109) or brain abscesses (110) was observed. However, it is unclear 
if archaea are directly involved in disease development or if their presence promotes the 
occurrence of pathogenic bacteria which are actually causing the disease. In IBD, 
M. stadtmanae is detectable in patients more frequently, and higher antibody titers against this 
archaeon compared to healthy individuals have been found (111). M. smithii and M. stadtmanae 
are both gut-associated archaea, yet they can also be detected in high amounts in bioaerosols of 
large, industrial animal farms (112). When these archaea are aerosolized and injected into the 
respiratory system of mice, they induce an immune response, at which M. smithii causes a mild 
immune activation and M. stadtmanae induces a considerably stronger response in form of lung 
hypersensitivity (113). These studies indicate that archaea might be harmful to farm workers 
and could cause chronic respiratory diseases.  
The different immune responses mounted by M. smithii and M. stadtmanae were also 
investigated in vitro using human PBMCs and monocyte-derived dendritic cells (moDCs). In 
both studies, M. stadtmanae induced a significantly stronger release of pro-inflammatory 
cytokines such as IL-1β and TNF-α compared to M. smithii (111, 114). As IL-1β is detectable 
after stimulation of moDCs with M. stadtmanae, the archaeon presumably activates the 
inflammasome. Moreover, Bang, et al. (114) observed that the expression of the co-stimulatory 
molecule CD86 and the C-C chemokine receptor type 7 (CCR7), which are both markers of 
activation and maturation of DCs, is increased on the cell surface of moDCs after stimulation 
with M. stadtmanae. The response to M. stadtmanae requires phagocytosis and endosomal 
acidification (114), which indicates that the actual recognition process takes place in an 
endosomal or intracellular compartment and not on the cell surface. In addition to pro-
inflammatory cytokines, M. stadtmanae also induces expression of different AMPs (114) and 
both, M. smithii and M. stadtmanae are susceptible to natural and synthetic AMPs in a low µM-
range (115). These studies demonstrate that the human immune system can specifically 
recognize and cope with different archaeal species. Yet, it is largely unknown if the host benefits 
from the presence of archaea or if certain archaeal species even harm the body and cause 
diseases. 
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3 Cellular Systems and CRISPR/Cas9 Technology 
3.1 BLaER1 Cell Line 
Besides PBMCs, primary monocytes and moDCs, the BLaER1 cell line is used in this 
study as a monocytic cell model system to investigate the response of myeloid immune cells 
against M. stadtmanae. Genetic manipulations like gene knockouts or construction of fusion 
proteins through the CRISPR/Cas9 system are applicable in these cells. BLaER1 cells are based 
on RCH-ACV, a B cell precursor leukemia cell line, which was genetically modified with a 
C/EBPα-ER-IRES-GFP construct by Rapino, et al. (116). These cells can be transdifferentiated 
into a monocytic cell line by cultivation with β-estradiol, interleukin 3 (IL-3) and macrophage 
colony-stimulating factor (M-CSF or CSF-1) for 7 days (Figure III-4). C/EBPα is an important 
transcription factor for monocytic and granulocytic cells during hematopoiesis (117). In 
BLaER1 cells, C/EBPα is translocated into the nucleus upon addition of β-estradiol which 
drives the transdifferentiation from a B lymphocytic cell line into a monocytic cell line. This 
process is supported by IL-3, a proliferative factor for myeloid cells (118) as well as M-CSF, a 
growth and differentiation factor for monocytes, macrophages and their respective progenitor 
cells (119). Rapino, et al. (116) showed that after transdifferentiation into monocyte/MΦ-like 
cells, BLaER1 cells become quiescent and functional phagocytes. Their expression profile is 
similar to that of primary macrophages. Furthermore, BLaER1 monocytes have a fully 
functional NLRP3 inflammasome complex and, in contrast to conventional monocytic cell lines 
like THP-1, alternative inflammasome activation can be triggered in BLaER1 monocytes (60). 
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Figure III-4. Transdifferentiation of BLaER1 B cells into monocytic cells. 
The BLaER1 cell line is based on the RCH-ACV cell line and was stably transduced with a C/EBPα-ER-IRES-
GFP construct. Transdifferentiation of BLaER1 B cells into BLaER1 monocytes is achieved by cultivation of the 
cells with β-estradiol for 7 days, which leads to the translocation of the myeloid transcription factor C/EBPα. 
M-CSF and IL-3 are added to support the transdifferentiation process. (C/EBPα, CCAAT/enhancer-binding 
protein alpha; ER, Estradiol receptor; GFP, Green fluorescent protein; IL-3, Interleukin 3; IRES, internal ribosomal 
entry site; M-CSF, Macrophage colony-stimulating factor). 
3.2 CRISPR/Cas9 as a Tool for Genetic Engineering 
CRISPR (Clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR 
associated protein 9) is a fast-developing technology which can be used for genetic 
manipulation of various cells and organisms. The technology is based on a mechanism that was 
originally described as an ancient defense mechanism of bacteria and archaea against phages 
and viruses (120, 121) and therefore often referred to as a prokaryotic adaptive immune system 
(122). CRISPR is used by microbes to excise foreign DNA from their genome. It comprises 
various enzymes including the RNA-guided nuclease Cas9 which is used for genetic 
engineering. Cas9 is associated with a CRISPR RNA (crRNA) array consisting of an auxiliary 
trans-activating crRNA (tracrRNA) and a guide RNA (gRNA). In order to simplify the system 
for genetic engineering, both RNAs can be fused to a single guide RNA (sgRNA) (123). The 
gRNA or sgRNA guides the Cas9 to a target DNA sequence via a 20 bp pairing (Figure III-5). 
This 20 bp sequence has only one restriction as a palindrome adjacent motif (PAM) must follow 
at the 3’-end of the 20 bp pairing sequence. The PAM sequence is species-dependent and can 
vary in its length. For the widely used Cas9 from Streptococcus pyogenes the PAM is ‘NGG’ 
(121). After binding of Cas9 to the target sequence, a double strand break (DSB) is catalyzed 
three bp downstream of the PAM. Once the target DNA is cleaved, mutations can be generated 
either randomly by non-homologous end joining (NHEJ) or specifically by homology-directed 
repair (HDR). In case of NHEJ, the cell repairs the DSB through a fast but error-prone 
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mechanism. This often leads to formation of insertion or deletion mutations (InDels). If these 
InDels are located within an exon, a frameshift can be introduced, and this can be used to 
generate a gene knockout. A donor (repair) template can be delivered with the Cas9 enzyme in 
order to use HDR to change specific nucleic acids or even add larger sequences like fluorescent 
proteins. The donor template can be given as ssDNA or dsDNA sequences or as plasmid DNA 
(124). 
 
 
Figure III-5. CRISPR/Cas9 as tool for genetic engineering in mammalian cells. 
The gRNA forms a complex with the Cas9 enzyme and directs it to complementary sequences in the gDNA of the 
cells. Binding between gRNA and the target sequence in the gDNA is only achieved if the PAM is present in the 
gDNA. After binding of Cas9 to the DNA, the enzyme catalytically cleaves the DNA via a DSB. The DSB is 
located three bases downstream of the PAM. The DSB is repaired by NHEJ which leads to the formation of InDel 
mutations. If a donor template is present, specific insertions can be introduced via HDR. (DSB, double strand 
break; gDNA, genomic DNA; gRNA, guide RNA; HDR, homology-directed repair; InDel, insertion or deletion 
of bases; NHEJ, non-homologous end joining; PAM, protospacer adjacent motif). 
To generate clonal BLaER1 knockout cell lines, a method adapted from Ran, et al. (123) 
is used (Figure III-6). At first, BLaER1 cells are transfected with plasmid which encodes a 
target gene-specific gRNA and the Cas9 enzyme which is linked via a T2A self-cleaving 
peptide to blue fluorescent protein (BFP) (125). BFP positive cells are single cell-sorted via 
fluorescence activated cell sorting (FACS) and expanded. The clones are finally analyzed for 
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InDel mutations in the target gene by sequencing and tracking of InDels by decomposition 
(TIDE) analysis. 
 
 
Figure III-6. Generation of BLaER1 KO cell lines using CRISPR/Cas9 
For generation of clonal BLaER1 KO cell lines, the cells are transfected with a CRISPR/Cas9 plasmid by 
electroporation. The plasmid encodes the SpCas9 enzyme, the gRNA and BFP as selection marker. After 
transfection, BFP+ cells are single cell sorted by FACS and expanded for 2-3 weeks. The occurrence of InDel 
mutations in the gene of interest in the different clones is analyzed by sequencing. Clones with frameshift 
mutations on all alleles are selected for further analysis and characterization. (BFP, blue fluorescent protein; FACS, 
fluorescence-activated cell sorting; gRNA, guide RNA; InDel, insertion or deletion mutations; KO, Knockout). 
Adapted and modified from Ran, et al. (123). 
 
4 Aim of this Study 
This study aims to investigate the interaction of human-associated methanogenic 
archaea with the immune system. The first part is focused on M. luminyensis, a methanogenic 
archaeon that was just recently described as an inhabitant of the human gut. Its ability to degrade 
TMA suggests that it provides benefits to the host. However, it is still unknown which effects 
M. luminyensis has on the immune system. Therefore, the strength and quality of the response 
of myeloid immune cells towards M. luminyensis will be analyzed. In addition, the effect of 
AMPs on the growth of M. luminyensis will be investigated.  
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The second part deals with the immune response of human myeloid cells against 
M. stadtmanae as it was shown that this archaeon is a strong inducer of pro-inflammatory 
cytokines. The exact recognition mechanism is unknown, as no archaeal MAMP could be 
identified yet. Thus, the study aims to identify the MAMP(s) from M. stadtmanae that is/are 
recognized by immune cells and to determine the receptor(s) involved in this process. The 
inflammasome components and their activation process, which are induced by M. stadtmanae, 
will also be investigated. Accordingly, the results can contribute to an improved understanding 
of the principles of archaeal recognition by the human immune system and how archaea might 
impact on inflammatory diseases. 
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IV Publication I: Immunogenic properties of the human gut-associated 
archaeon Methanomassiliicoccus luminyensis and its susceptibility to 
antimicrobial peptides 
Bang C, Vierbuchen T, Gutsmann T, Heine H, Schmitz RA 
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1 Abstract 
The methanogenic archaeon Methanomassiliicoccus luminyensis strain B10T was 
isolated from human feces just a few years ago. Due to its remarkable metabolic properties, 
particularly the degradation of trimethylamines, this strain was supposed to be used as 
“Archaebiotic” during metabolic disorders of the human intestine. However, there is still no 
data published regarding adaptations to the natural habitat of M. luminyensis as it has been 
shown for the other two reported mucosa-associated methanoarchaea. This study aimed at 
unraveling susceptibility of M. luminyensis to antimicrobial peptides as well as its 
immunogenicity. 
By using the established microtiter plate assay adapted to the anaerobic growth 
requirements of methanogenic archaea, we demonstrated that M. luminyensis is highly sensitive 
against LL32, a derivative of human cathelicidin (MIC=2 µM). However, the strain was highly 
resistant against the porcine lysin NK-2 (MIC=10 µM) and the synthetic antilipopolysaccharide 
peptide (Lpep) (MIC>10 µM) and overall differed from the two other methanoarchaea, 
Methanobrevibacter smithii and Methanosphaera stadtmanae in respect to AMP sensitivity. 
Moreover, only weak immunogenic potential of M. luminyensis was demonstrated using 
peripheral blood mononuclear cells (PBMCs) and monocyte-derived dendritic cells (moDCs) 
by determining release of pro-inflammatory cytokines.  
Overall, our findings clearly demonstrate that the archaeal gut inhabitant M. luminyensis 
is susceptible to the release of human-derived antimicrobial peptides and exhibits low 
immunogenicity towards human immune cells in vitro – revealing characteristics of a typical 
commensal gut microbe. 
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2 Introduction 
The human gut microbiota is by far described to be dominated by bacteria (126), 
although a large number of microeukaryotes, fungi, viruses as well as archaea also form part of 
it (127). In contrast to bacteria, fungi and viruses, the immunological impact of archaea on the 
human immune homeostasis has rarely been described. This underrepresentation is mainly 
because still no archaeal pathogen is known and the challenges of growing these 
microorganisms in the laboratory.  
The two methanoarchaeal strains Methanosphaera stadtmanae and Methanobrevibacter 
smithii were isolated and cultivated from human feces over 30 years ago (128, 129). Recently, 
human immune cell activation in response to these two strains was investigated (111, 114) and 
it was shown that they are prone to the lytic effects of antimicrobial peptides, similarly to those 
described for bacteria, though they differed in sensitivities (115). Only recently, several strains 
from the newly identified methanogenic order Methanomassiliicoccales were also found to 
inhabit the human intestine with low abundances (130-132) but only the strain 
Methanomassiliicoccus luminyensis strain B10T was cultured and biochemically characterized 
in 2014 (133). Importantly, this strain was shown to degrade trimethylamine (TMA) via H2-
dependent reduction of methyl-compounds in the process of methanogenesis (133). Thus, the 
authors hypothesized that human-associated Methanomassiliicoccales strains might be used as 
probiotics against metabolic disorders associated with TMA produced by gut bacteria (103). 
These disorders include trimethylaminuria (134) as well as the development of cardiovascular 
(135) and chronic kidney disease (136). However, besides its natural metabolic capacity to 
diminish TMA very little is known about the functional role of Methanomassiliicoccales within 
the human intestine and its microbiota. When discussing a potential use of 
Methanomassiliicoccales as “Archaebiotics” (103), particularly their impact on human immune 
homeostasis has to be considered.  
As mentioned above, the predominant mucosa-associated archaeal strains M. 
stadtmanae and M. smithii appear to have highly different effects on human immune cells, 
particularly with respect to their overall immunogenicity and sensitivity to mammalian-derived 
antimicrobial peptides (AMPs) (114, 115). The corresponding information is still lacking for 
the new order of Methanomassiliicoccales but it is crucial for a holistic view on its functional 
role within the human intestine. Therefore, the current study aimed at evaluating those 
parameters for the cultivable strain M. luminyensis.  
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3 Materials and Methods 
Ethics statement 
Approval for these studies was obtained from the Institutional Ethics Committee at the 
University of Lübeck (Lübeck, Germany; Az. 12-202A) according to the Declaration of 
Helsinki. All donors gave written informed consent. 
 
Growth of M. luminyensis 
M. luminyensis (DSM 25720) was obtained from the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) and was grown at 37 °C 
in 5 or 50 ml minimal medium (Medium 120, DSMZ) under strict anaerobic conditions as 
described earlier (137). The medium was reduced with the reductant cysteine (2 mM final 
concentration) prior to inoculation, 150 mM methanol was added as carbon and energy source 
and 152 kPa H2/CO2 (80/20 vol/vol) was used as gas phase. To prevent bacterial contamination 
the medium was supplemented with 100 μg/ml ampicillin. M. luminyensis cell numbers were 
counted in precultures by using a Thoma counting chamber and concurrent determination of 
optical turbidity at 600 nm (OD600) during the growth period. For immune cell stimulation, 
exponentially growing M. luminyensis cells were harvested at 3,200 x g for 30 min, washed and 
resuspended in 50 mM Tris-HCl (pH 7.0).  
 
Antimicrobial peptides (AMPs) 
The AMPs tested in this study were a derivative of the human cathelicidin LL37 (LL32) 
(138), one derivative of porcine NK-lysin (NK2) (139), and a synthetic antilipopolysaccharide 
peptide Lpep 19-2.5 (140) (all purified from chemical peptide synthesis, and kindly provided 
by O. Holst, Division of Structural Biochemistry, Research Center Borstel, Borstel, Germany). 
Peptides were stored in stock solutions at -20°C and diluted in anaerobic Aquadest prior to use. 
 
Microtiter plate assay for AMP susceptibility test 
The antimicrobial activity of the peptides against M. luminyensis was determined by 
growth inhibition in microtiter plates as described earlier (115). In brief, 2x107 cells from mid-
exponential growth phase of precultures were inoculated into 250 µl minimal medium in U-
bottom polystyrene microtiter plates (MICROLON® - Greiner Bio-One GmbH, Frickenhausen, 
Germany) and supplemented with different AMP-concentrations. Incubation of these cultures 
was performed in an anaerobic jar (Schuett-Biotec GmbH, Göttingen, Germany) and 152 kPa 
H2/CO2 was continuously supplied during incubation except during monitoring of optical 
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densities in a plate reader that was performed in an anaerobic chamber. After stationary phase 
was reached, cultures were randomly picked for phase contrast microscopy.  
 
Cell culture 
For peripheral blood mononuclear cell (PBMC) isolation, heparinized blood of donors 
was prepared by Ficoll (Merck KGaA, Darmstadt, Germany) separation (141). PBMCs were 
resuspended at a concentration of 2×106 cells/ml in RPMI medium (Merck KGaA) 
supplemented with 10% FCS (Merck KGaA) and antibiotics (100 U/ml penicillin and 
100 µg/ml streptomycin (both Merck KGaA). Preparation of monocyte-derived dendritic cells 
was performed by harvesting PBMCs as described above and subsequent isolation of 
monocytes by counter flow elutriation centrifugation (142). MoDCs were generated by addition 
of interleukin 4 (IL-4) and granulocyte-macrophage colony stimulating factor (GM-CSF) to 
PBMCs in 6-well plates for 7 days as described previously (143), harvested and re-cultured in 
complemented RPMI medium for stimulation experiments. PBMCs as well as moDCs were 
grown and incubated in a humidified atmosphere of 5% carbon dioxide at 37 °C. 
 
Cytokine measurements 
Cytokine releases of stimulated PBMCs and moDCs were quantified after 20 h by using 
commercial ELISA Kits (Life Technologies GmbH, Darmstadt, Germany) specific for IL-1β 
and TNF-α in supernatants.  
 
Confocal laser scanning microscopy  
For confocal laser scanning microscopy 105 moDCs were incubated at 37 °C for 2 h on 
VI channel µ-slides (Ibidi, Martinsried, Germany) before stimulation with 107 Fluorescein 
isothiocyanate (FITC)-labeled (1 mg/ml, Sigma-Aldrich Chemie GmbH, Hamburg, Germany) 
methanoarchaeal cells for 16 h. Subsequently, cells were fixed in 3% paraformaldehyde 
(Biolegend) and labeled with Hoechst 33342 (3 µM, (Life Technologies GmbH)). Images were 
captured using Leica SP5 confocal microscope (Leica Microsystems GmbH, Wetzlar, 
Germany) with Leica confocal software. 
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Statistical analysis 
The data were analyzed for statistical significance using Graph Pad Prism 7.02 software. 
P values ≤ 0.05 were considered to be statistically significant.  
4 Results 
The present study mainly aimed at evaluating the sensitivity of M. luminyensis to 
epithelial-derived antimicrobial substances as well as its recognition by humane immune cells 
with respect to the activation of pro-inflammatory pathways. 
4.1 Growth inhibition of M. luminyensis by AMPs 
M. luminyensis is a coccoid methanoarchaeon that is very small in size (approximately 
0.85 µm in diameter) (130). Earlier studies have shown that this methanoarchaeon can grow on 
methanol and trimethylamines as carbon sources, but for energy metabolism urgently needs 
hydrogen as electron donor (130). To meet the specific growth conditions of M. luminyensis, 
the microtiter plate assay that was recently established for anaerobic microorganisms (115) was 
adjusted. Under optimized growth conditions at 37 °C (see Material and Methods) stationary 
growth phase of M. luminyensis was reached after 200 h in 250 µl at an optical density of 
approximately 0.6 (Fig. 1A, Control). Cell morphology after growth in microtiter wells was 
assessed by phase contrast microscopy (Fig. 1C, Control). Microscopy also served for exclusion 
of contaminations within the cultures. 
Determination of minimal inhibitory concentrations (MIC) of selected AMPs was 
performed by adding various concentrations from 5 nM up to 20 µM at the beginning of growth. 
LL32 is the shortest active unit of human-derived cathelicidin (138), whereas NK2 is a lysin 
originally isolated from pig (139) and Lpep19.2-5 is a synthetically modified peptide optimized 
for therapeutic use (144). Not expected, complete growth inhibition of M. luminyensis by LL32 
was obtained already at low concentrations (2 µM, Tab. 1), whereas inhibition by NK2 as well 
as Lpep19.2-5 was observed only at relatively high concentrations, 10 µM and 20 µM 
respectively. In addition, microscopic evaluation during the stationary phase of M. luminyensis 
in the presence of AMPs revealed different morphological properties. LL32 resulted in swelling 
of cells (up to 50% of cell size), which in case of strongly effected cells lead to release of 
cytoplasmic material from the cells (Fig. 1C). In contrast, micrographs of M. luminyensis after 
incubation with high concentrations of NK2 and Lpep19.2-5 revealed increased cell 
coagulation, however only minor effects on overall cell morphology (Fig. 1C).  
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Figure 1:Growth inhibition of M. luminyensis by various AMPs 
(A) 2x107 cells of M. luminyensis incubated with depicted concentrations of LL32 at 37 °C in 250 µl minimal 
medium under anaerobic conditions (see Materials and Methods). Turbidity of cultures at 600 nm (OD600) was 
monitored over time. Error bars represent standard deviation of three biological replicates in one experimental 
setup. (B) 2x107 cells incubated with various concentrations of the peptides LL32, Lpep 19-2.5 or NK2 at 37 °C 
in 250 µl minimal medium. Turbidity of control cultures at 600 nm (OD600) after 200 h of growth was set to 100%. 
Error bars represent standard deviation of three biological replicates. (C) Phase-contrast micrographs taken after 
200 h of growth with the indicated concentrations of the respective added AMPs. 
4.2 Immune cell activation by M. luminyensis  
In the current study human PBMCs as well as moDCs were used to evaluate the 
immunogenic potential of M. luminyensis, as previously done for the other investigated mucosa-
associated methanoarchaea. 1x106 or 1x107 cells of M. luminyensis were added to preparations 
of 1x105 PBMCs as well as moDCs. After 20 h of incubation, supernatants were taken and 
cytokine release of TNF- and IL-1 was measured by ELISA. M. stadtmanae served as 
positive control in these experiments due to its capability to induce very high cytokine releases 
in primary human immune cells (112, 114). Compared to M. stadtmanae, stimulation with M. 
luminyensis only led to low amounts of released pro-inflammatory cytokines TNF- and IL-1 
in both, PBMCs (Fig. 2A) and moDCs (Fig. 2B). This effect was observed in a concentration-
dependent manner as was also shown for the control stimulus M. stadtmanae (Fig. 2A+B, 1x106 
and 1x107 cells). In addition to cytokine release, phagosomal uptake by moDCs was evaluated 
by using CLSM. 1×107 FITC-labeled methanoarchaeal cells were added to 1×105 moDCs 
seeded in VI channel µ-slides. After 16 h of incubation, DNA was stained with Hoechst 33342 
and visualized using confocal microscopy. Whereas the uptake of M. stadtmanae occurred in 
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high numbers, M. luminyensis was only rarely found to be phagocytosed by moDCs as depicted 
in Fig. 2C. In addition, the typical change of morphology after activation of immune responses 
in moDCs such as formation of dendrites was only observed for the positive control 
M. stadtmanae.  
5 Discussion 
Although bacteria represent the major microbial part of the human gut ecosystem, 
recently available molecular tools revealed the constant presence of archaeal species in the 
gastrointestinal tract (145). Besides the most prevalent methanoarchaeal strains M. stadtmanae 
and M. smithii, three novel methanoarchaeal species belonging to the Methanomassiliicoccales 
were isolated and their respective genomes sequenced during the last years (130-132). Due to 
their metabolic capability to degrade trimethylamine (TMA) (133) a potential application of 
naturally occurring Methanomassiliicoccales members as “Archaebiotics” was proposed 
recently (103). Since information on the general immunogenic impact of these strains is still 
missing, the current study mainly aimed to elucidate the molecular cross-talk between 
components of the human immune system and the cultivable strain M. luminyensis.  
5.1 Susceptibility of M. luminyensis to AMPs 
As a part of the human microflora, methanogenic archaea such as M. stadtmanae, 
M. smithii and M. luminyensis are exposed to various epithelial as well as immune defense 
mechanisms that prevent invasion or colonization of organs and maintain homeostasis (146). 
One crucial line of epithelial defense is the secretion of AMPs that represent an essential part 
of immunity within the human intestine (147). Since AMPs in general exhibit various structural 
motifs, structurally different AMPs, like a cathelicidin and a NK-lysin derivative as well as a 
synthetic antilipopolysaccharide peptide (Lpep) were chosen in order to examine the general 
susceptibility of M. luminyensis. Moreover, lytic effects of these AMPs on other mucosa-
associated methanoarchaeal strains were demonstrated earlier (115). We demonstrated that M. 
luminyensis is indeed susceptible to the human AMP-derivative LL32 in low µM-ranges (see 
Table 1). In addition, we show that this strain is more resistant to AMPs from other origins such 
as NK2 and Lpep19-2.5. The latter results resemble those of the other two mucosa-associated 
methanoarchaeal strains, M. stadtmanae and M. smithii summarized in Table 1. When 
compared to the sensitivity of the other two strains, M. luminyensis appears to be similarly 
resistant against the lytic effects of NK2 and Lpep19.2-5 as shown for M. stadtmanae (115). 
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Figure 2: Immune cell activation after stimulation with M. luminyensis 
Cytokine release after stimulation of 1×105 PBMCs (A) as well as 1×105 moDCs (B) with 1×106 and 1×107 
M. luminyensis or M. stadtmanae cells for 20 h was quantified using commercial ELISA-Kits. Unstimulated cells 
(Med. ctrl.) were used as negative controls. Depicted data are means of at least 3 independent biological replicates 
with their respective standard errors of the mean (SEM). Values are compared to medium control. ns: not 
significant, * P≤0.05, ** P≤0.01, *** P≤0.001 (one-way ANOVA with Bonferroni post hoc test). (C) 1×105 
moDCs were stimulated with 1×107 FITC-labeled methanoarchaeal cells in VI channel µ-slides for a period of 
16 h. After incubation, moDCs were washed, fixed with 3% paraformaldehyde and DNA was labeled with Hoechst 
33342. Images were captured using Leica SP5 confocal microscope with Leica confocal software and are 
representative of the respective samples (three independent biological replicates). (D) Phagocytosis rate of M. 
stadtmanae and M. luminysensis by moDCs was determined by counting phagocytosed archaeal cells in image 
sections of three biological replicates. Values are compared to each-other. *** P≤0.001 (two-tailed unpaired t-
test). 
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However, with respect to this, LL32 showed higher activity against M. luminyensis. On the 
other hand, M. luminyensis is more resistant against all peptides tested than M. smithii. 
Concerning the latter it has to be mentioned that based on the small cell size of M. luminyensis, 
twice as much cells were used for inoculation (for the reason of growth monitored by turbidity). 
During earlier studies it was already shown that the cell membrane charge of the tested 
methanoarchaeal strains, as well as the cell wall structure, strongly influence the interaction and 
lytic activity of the used cationic charged AMPs (115, 148, 149). Although the cell wall 
composition of M. luminyensis has not yet been fully characterized, transmission electron 
micrographs indicated a double-layer cell wall with one thin electron-dense layer and one thick 
transparent layer for this strain (130). As has been shown for M. stadtmanae and M. smithii, 
M. luminyensis was found to behave like a Gram-positive in Gram staining assays suggesting 
that its cell wall might be also composed of pseudomurein (150), however this speculation has 
to be proven in future studies. With respect to the cell membrane composition, a recent 
publication demonstrated an unusual membrane lipid composition for M. luminyensis (151). 
Whereas the cell membranes of M. smithii and M. stadtmanae are composed of already high 
amounts of caldarchaeols (13 - 40%), the cell membrane of M. luminyensis contains 
approximately 58% (151). These caldarchaeols form mono-layer tetraether lipids and thus 
exhibit a high ordered structure of the membrane. Besides, the cell membrane of M. luminyensis 
has been shown to contain only low amounts (~ 33%) of hydrophilic head groups, such as 
phosphatidylglycerol, and thus probably is less negatively charged, but stabilized by high 
amounts of lipids with glycosidic head groups (151, 152). Thus, the differences obtained for 
M. luminyensis might be mainly due to its unique cell wall and cell membrane architecture (130, 
151). With respect to the effects of AMPs on structural changes of M. luminyensis, phase-
contrast micrographs revealed swelling of cells after incubation with LL32, but not after 
treatment with the other peptides. This swelling was most likely due to the osmotic stress after 
lysis of the cell membrane. During the treatment with NK2 and Lpep19.2-5 M. luminyensis 
cells appeared rather to coagulate – an effect that was also observed for M. stadtmanae during 
earlier studies and thus coagulation of the cells might resemble a general preventive function 
against the lytic effects of naturally-occurring AMPs (115). In conclusion, the results of AMP-
treatment regarding growth inhibition and morphological changes of M. luminyensis revealed 
that the cell membrane as well as the cell wall appears to be well adapted to mammalian-derived 
antimicrobial peptides that obtain homeostasis within the intestine.  
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Table 1: Antimicrobial activity of various AMPs against methanogenic archaea  
(MIC minimal inhibitory concentration) 
 
5.2 Immunogenic potential of M. luminyensis  
Previous studies on immune cell activation and responses focusing on cytokine release 
and CLSM demonstrated that the mucosa-associated methanoarchaeons M. smithii and 
M. stadtmanae led to differential immune cell activation and responses (112, 114). Based on 
these results, the question arose, if and how human immune cells respond to M. luminyensis. 
Interestingly, we found that stimulation of human immune cells with M. luminyensis only led 
to low amounts of the released cytokines TNF- and IL-1 as it has been demonstrated for the 
commensal methanoarchaeal strain M. smithii. In addition, phagocytosis by moDCs as well as 
the formation of typical dendrites revealing activation was only rarely seen after stimulation 
with M. luminyensis, whereas strong activation was obtained after stimulation with 
M. stadtmanae as has been observed earlier (114). These findings suggest that – as it is known 
for bacteria – diverse (methano)archaeal strains appear to possess structurally different 
molecular patterns, which serve to a greater or lesser extent as immune activators.  
To date, the respective involved human receptor that recognizes archaeal molecular 
patterns has not been described. However, the pseudomurein-containing cell wall of both, 
M. stadtmanae and M. smithii, is surrounded by a second layer composed of 
heteropolysaccharides whose structure remains to be elucidated (153). As mentioned above, the 
cell wall architecture of M. luminyensis also appears to be composed of two layers with different 
structural properties (130). Since numerous membrane-bound and extracellular receptors are 
known to be involved in the recognition of bacteria-associated heteropolysaccharides (154), it 
is conceivable that the outer layer of M. luminyensis as well as M. smithii cell walls prevents 
these strains from phagocytosis by human immune cells. However, in order to support this 
hypothesis, data on the respective involved human pattern-recognition receptor as well as on 
the chemical properties of mucosa-associated methanoarchaeal cell wall composition are 
urgently needed.  
 MIC (µM) Ref. 
Strain LL32 NK2 Lpep 19-2.5  
M. luminyensis 2 10 > 10 This study 
M. stadtmanae 5 10 > 10 (115) 
M. smithii 1 3 3 (115) 
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Recent studies with particular focus on genomic adaptions demonstrated that 
M. luminyensis appears to be the less common gut inhabitant when compared to other members 
of the Methanomassiliicoccales in the human intestine (155). In detail, phylogenetic analysis of 
the so far in human stool detected Methanomassiliicoccales strains revealed that M. luminyensis 
is more related to soil and sediment methanogens, whereas the later described strain 
"Candidatus Methanomethylophilus alvus" was found to be genetically more related to 
gastrointestinal methanogens [11]. The additional identified strain "Candidatus 
Methanomassiliicoccus intestinalis” is phylogenetically also more related to soil and sediment 
methanogens, however it has a reduced genome and an up to 20-fold higher prevalence when 
compared to its closest relative M. luminyensis. Thus, Borrel and colleagues concluded that 
M. luminyensis might not be the best model to study the interactions of the representatives of 
this archaeal order with their human host (155). Indeed, it could be speculated that other 
members of Methanomassiliicoccales might resemble different immunogenetic properties 
when compared to M. luminyensis. However, with respect to its metabolic capabilities of TMA 
depletion, its general appearance in the human intestine and the herein observed overall mild 
human immune response particularly of this Methanomassiliicoccales strain might be proposed 
for a potential application as an “Archaebiotic” (103).  
6 Conclusion 
Taken together, this study substantiated adaptation of the intestinal archaeal strain 
M. luminyensis to its natural habitat and underlines previous findings on diverse physiological 
and immunomodulatory roles of other mucosa-associated methanoarchaeal strains in the human 
intestine.  
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1 Abstract 
The archaeon Methanosphaera stadtmanae is a member of the gut microbiota; yet, the 
molecular cross-talk between archaea and the human immune system and its potential 
contribution to inflammatory diseases has not been evaluated. Although archaea are as bacteria 
prokaryotes, they form a distinct domain having unique features such as different cell wall 
structures and membrane lipids. So far, no microbe-associated molecular patterns of archaea 
which activate innate immune receptors have been identified. By stimulating human myeloid 
cells with M. stadtmanae and purified archaeal nucleic acids, we identified both the 
microorganism and its RNA as potent stimuli for the innate immune system. To dissect the 
recognition and activation pathways induced by M. stadtmanae, human monocytic BLaER1 
knockout cells were generated using the CRISPR/Cas9 system targeting components of TLR 
and inflammasome signaling. While the recognition of M. stadtmanae is mediated by TLR7 
and TLR8, activation of the NLRP3 inflammasome depends solely on TLR8 engagement. 
Notably, this process resembles hallmarks of both the canonical and the recently described 
alternative inflammasome activation. Thus, we have demonstrated for the first time the specific 
recognition of and response to an archaeon by human cells at the molecular level. 
2 Introduction 
During the last decade, the extensive use of modern molecular approaches has revealed 
the existence of trillions of microorganisms in the human intestine that form a complex 
ecological community (126, 156). Though these microorganisms interact closely with their 
human hosts to provide many physiological benefits, this community has also been implicated 
in the development of an increasing number of diseases – in particular, those associated with 
chronic inflammation (157). Although much research has focused upon bacterial species (which 
dominate the human gut microbiota), species of the archaeal domain are also stable components 
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of the gut microbiota (127, 158, 159). Relatively little is known as to how these less-studied 
organisms influence human health, although several studies have suggested that methanogenic 
species of archaea, such as Methanosphaera stadtmanae, might be involved in the development 
of systemic diseases such as obesity (104, 105, 160, 161), cancer (162-164), lung 
hyperresponsiveness (113) and inflammatory bowel disease (IBD) (111). Understanding the 
molecular mechanisms through which these microorganisms induce inflammation is thus an 
important step in uncovering how such diseases might develop. 
M. stadtmanae is currently known to be the second most abundant archaeon in the 
human intestine (94, 129). During the last few years, we and others have demonstrated the high 
immunogenic potential of M. stadtmanae in human peripheral blood mononuclear cells 
(PBMCs) and monocyte-derived dendritic cells (moDCs) (111, 112, 114) – strong innate and 
adaptive immune responses, including the secretion of pro-inflammatory cytokines TNF-α and 
IL-1β, were detected. Although neither the pattern recognition receptors (PRRs) nor the 
respective microbe-associated molecular patterns (MAMPs) involved in the response to 
M. stadtmanae have yet been identified, we showed previously that phagocytosis and 
endosomal acidification are required for recognition of M. stadtmanae and resulting cytokine 
release by both human PBMCs and moDCs (114). IL-1β secretion, as seen following exposure 
to M. stadtmanae, results from activation of the inflammasome, a cytosolic multiprotein 
complex required for processing pro-IL-1β (165). In general, inflammasomes consist of a 
cytosolic sensor protein, the adaptor protein ASC and the effector caspase caspase-1. This 
sensor protein can be a member of the NLR family or AIM2, a cytosolic DNA sensor (44). 
NLRP3 is the best-studied member of the NLR family and senses cellular stress signals like 
potassium efflux and lysosomal leakage (46).  
Endosomal recognition of microorganisms often shows an anti-viral type response that 
is induced through the detection of nucleic acids and includes type I interferons (IFN-α/β) (31). 
As a result, we hypothesized that intracellular PRRs might recognize archaeal cellular 
structures, in particular, their nucleic acids and potentially leading to inflammasome activation. 
Various cytosolic or endosomal receptors have been identified that are capable of sensing 
nucleic acids of bacterial or viral origin (29) and might also be involved in the detection of 
M. stadtmanae – for example, Toll-like receptors (TLRs), nucleotide-binding oligomerization 
domain receptors (NLRs), and retinoic acid-inducible gene 1-like receptors (RLRs). However, 
receptor silencing and inhibition using RNAi constructs or antagonists, are often challenging 
and inefficient in primary human immune cells (166), and this makes it difficult to identify 
which of these receptors might recognize such archaea. We therefore adopted a loss-of-function 
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approach using CRISPR/Cas9-mediated mutagenesis to obtain stable human knockout cells 
with a particular focus on intracellular receptors and signaling molecules.  
Through this approach, we identified archaeal RNA as the pivotal MAMP of 
M. stadtmanae that activates TLR8 and, to a lesser extent, TLR7. Moreover, M. stadtmanae 
triggers a so far undescribed TLR8-dependent NLRP3 inflammasome activation pathway in 
human monocytes that shares elements of canonical and alternative inflammasome activation. 
Thus, our findings describe in detail the molecular mechanisms by which M. stadtmanae 
induces inflammatory responses in human monocytes, which will provide the first steps towards 
understanding how archaea interact with their host in the gut microbiota and elucidating the 
potential role of these microorganisms in inflammatory diseases such as IBD or lung 
hyperresponsiveness. 
 
3 Results 
3.1 M. stadtmanae RNA is a MAMP inducing an antiviral type I/III 
interferon response in human monocytes 
The aim of this study was to elucidate the cellular receptors and MAMPs that are 
involved in sensing the methanogenic archaeon, M. stadtmanae (98, 111). Based on our 
hypothesis that intracellular PRRs and nucleic acids might be involved, recognition of 
M. stadtmanae should lead to an anti-viral type cellular immune response. Thus, we first 
analyzed the time-dependent mRNA expression of type I and type III IFNs in moDCs (Figure 
1A) and PBMCs (Figure 1B). Expression of the genes encoding IFN-α14, IFN-β and IFN-λ1 
(IL-29) was upregulated in PBMCs and moDCs upon exposure to M. stadtmanae. As NF-κB, 
IRF1 and IRF5 are reported to be involved in the response against pathogens and particularly 
IRF5 in the induction of type I and type III IFN responses (167), we next examined the 
subcellular localization and expression of these transcription factors following cellular 
activation by M. stadtmanae. Using confocal microscopy, we observed that 4 h after 
stimulation, all three transcription factors were translocated from the cytoplasm into the nucleus 
(Figure 1C). These findings indicated that these transcription factors were active, and provided 
further evidence that exposure to M. stadtmanae induces an anti-viral type I/III IFN response. 
 As such immune responses are often induced in response to viral or bacterial 
nucleic acids, either detected in the cytosol or endocytic compartments, and given that the 
response to M. stadtmanae is also dependent on phagocytosis (114), we hypothesized that the 
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nucleic acids from M. stadtmanae might similarly act as MAMPs and activate immune cells. 
To determine the immunogenicity of archaeal nucleic acids, we transfected purified DNA or 
RNA into PBMCs using the liposomal transfection reagent DOTAP, and analyzed the secretion 
of two pro-inflammatory cytokines, TNF-α and IL-1β. Transfection of archaeal DNA did not 
induce secretion of TNF-α or IL-1β in human PBMCs (Figure S1). In contrast, RNA from 
M. stadtmanae induced TNF-α and IL-1β release from moDCs (Figure 1D), as well as PBMCs 
(Figure 1E), which was absent upon addition of RNase A to the transfection mix. To analyze if 
the RNA-dependent activity is restricted to certain RNA species, we purified single ribosomal 
5S, 16S, and 23S RNA and examined their capability to activate moDCs (Figure 1F) and 
PBMCs (Figure 1G). In this experimental setup, no significant changes in cytokine secretion 
by the different rRNA fractions were observed.  
3.2 M. stadtmanae is recognized by innate immune cells through TLR7 and 
TLR8 
Having demonstrated that RNA from M. stadtmanae is a potent activator of human immune 
cells, our next step was to identify the cognate PRR involved in its recognition by human 
monocytes. Since knockdown approaches in primary human monocytes and dendritic cells 
were unable to achieve a complete inhibition of gene expression (data not shown), we decided 
to instead use the BLaER1 cell line (116), in which genetic modifications and stable knock-out 
via CRISPR/Cas9 are possible (60). This line is a B-ALL-derived cell line that can be 
transdifferentiated into a monocyte-like cell type, so we first confirmed whether these BLaER1 
cells, upon differentiation, respond to M. stadtmanae in a similar manner to PBMCs and 
moDCs, and thus whether they would provide a suitable model in which to unpick the molecular 
mechanisms involved in recognition of this archaeon. Exposure of BLaER1 monocytes to 
M. stadtmanae led to an increase in TNF-α, IL-6 and IL-1β secretion 18 h after stimulation, in 
a similar manner to that observed with moDCs. Using Cytochalasin D, an inhibitor of 
phagocytosis, and Bafilomycin A1, an inhibitor of endosomal acidification, we confirmed that 
the recognition of M. stadtmanae in BLaER1 monocytes is also dependent on both mechanisms 
(Figure S2A), similarly to our findings in human moDCs (114). The phagocytosis of 
M. stadtmanae by BLaER1 monocytes was verified by confocal microscopy (Figure S2B). 
These data confirmed the use of BLaER1 monocytes as a suitable model system for this study. 
Our data suggest that M. stadtmanae RNA is detected by intracellular PRRs in human 
monocytes. All human nucleic acid-specific TLRs (TLR3, TLR7-9) are located in the 
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Figure 1. M. stadtmanae and its RNA induce an immune response with antiviral characteristics. 
(A, B) The expression of genes encoding for IFN-α14, IFN-β and IFN-λ1 in moDCs (A) and PBMCs (B) after 
stimulation with M. stadtmanae for 3, 6 and 12 h was measured by qRT-PCR. The log2 ratios of all three gene to 
the reference gene HPRT are presented. The data from at least three different donors are shown as the mean ± 
SEM (n = 3-4). ns: not significant, * P≤0.05, ** P≤0.01, *** P≤0.001 (all compared to unstimulated control group; 
repeated measures one-way ANOVA with Dunnett post hoc test). (C) Confocal microscopy of cellular location of 
NF-κB p65, IRF1, and IRF5 (green) in moDCs after stimulation with M. stadtmanae for 4 h by immunolabelling. 
Nuclei were counterstained with Hoechst 33342 (blue). Scale bars: 10 µM. The images shown are representative 
examples from one of three independent experiments (n = 3). (D, E) ELISA of TNF-α and IL-1β in the 
supernatants of stimulated moDCs (D) or PBMCs (E) after 18 h. Cells were either untreated, treated with 107 cells 
of M. stadtmanae, or with 5 µg/ml of total RNA from M. stadtmanae. RNA was complexed to DOTAP and pre-
treated for 30 min at 37 °C with RNase A where indicated. (F, G) ELISA of TNF-α and IL-1β in the supernatants 
of moDCs (F) or PBMCs (G) stimulated for 18 h with 107 cells of M. stadtmanae or 2.5 µg/ml of purified rRNAs 
(complexed to DOTAP). In (D-G), the data shown are the mean ± SEM of at least four different donors (n = 4-7). 
ns: not significant, * P≤0.05, ** P≤0.01 (one-way ANOVA with Tukey post hoc test; in (D, E) all compared to 
unstimulated control group and in (F, G) the rRNA fractions are compared to each other). 
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endosomal compartment, and these receptors rely on the protein UNC93B1, which is mandatory 
for their trafficking from the endoplasmic reticulum (ER) to the endosomes (168). To confirm 
our assumption that M. stadtmanae is recognized by endosomal TLRs, we generated 
UNC93B1-/- cells (see Figures S3A and S3B for further information regarding all CRISP/Cas9-
generated BLaER1-KO cells in this study) and determined whether these cells retained an 
ability to respond upon exposure to archaeal cells. UNC93B1-/- BLaER1 monocytes failed to 
secrete any TNF-α and IL-1β after stimulation with M. stadtmanae (Figure 2A), confirming the 
involvement of either TLR3, or TLR7-9 in the induction of cytokine responses.  
We next generated KO cells lacking MyD88 or TRIF, which are the central adapter 
molecules used by different TLRs for signal transduction (169). Upon exposure to 
M. stadtmanae, TRIF-/- cells showed a slightly decreased but still high secretion of TNF-α and 
no reduction in the levels of IL-1β and RANTES (CCL5), compared to that induced in 
stimulated WT cells (Figure 2B). In contrast, this response was completely absent in MyD88-/- 
cells exposed to this archaeal species (Figure 2B). Our results showed that M. stadtmanae is 
recognized through one or more MyD88-dependent TLRs by human monocytes. 
As TLR9 recognizes DNA, TLR3 signals via TRIF, and human TLR7 and TLR8 are the 
only RNA-specific receptors that signal via MyD88 and are dependent on UNC93B1, we 
assumed that either or both of TLR7 and TLR8 were involved in the detection of 
M. stadtmanae. To identify which of these receptors recognizes M. stadtmanae, we generated 
single-gene knockout cell lines for each these receptors, as well as a double knockout (TLR7-/-
×TLR8-/-) cell lines. Using these cells, we demonstrated that the secretion of TNF-α in response 
to M. stadtmanae can be induced via TLR7 as well as TLR8, with reduced levels of cytokine 
secretion detected compared to that produced by stimulated WT cells in both knockout cell 
lines. TLR8-/- cells did, however, show a greater decrease in TNF-αsecretion compared to that 
of the TLR7-/- cells (Figure 2C). Unexpectedly, the secretion of IL-1β was entirely dependent 
on TLR8, as no secretion of this cytokine was detected in TLR8-/- cells after stimulation with 
M. stadtmanae. The TLR7/8 agonist R848, the TLR7 agonist CL264, and the TLR8 agonist 
TL8-506 were used as controls to confirm the specificity of the clones used in this study (Figure 
2C). Additionally, we transfected purified RNA from M. stadtmanae into TLR7-/-, TLR8-/-, and 
TLR7-/-×TLR8-/- BLaER1 monocytes using DOTAP and measured the secretion of TNF-α and 
IL-1β after 18 h. Similar to whole archaea, RNA from M. stadtmanae is recognized by TLR7 
and TLR8, but the knockout of TLR8 revealed that the latter receptor has a stronger effect 
(Figure 2D).  
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Recently, TREML4 was shown to be involved in the recruitment of MyD88 to TLR7, 
thereby amplifying its signaling(170). However, TREML4-/- BLaER1 monocytes showed no 
alterations in secretion of IL-6 or TNF-α after stimulation with M. stadtmanae or different 
TLR7/8 agonists (Figure S4) indicating that this protein, at least in human monocytes, is not 
essential for TLR7/8 activation. To further characterize the individual roles of TLR7 and TLR8 
in the response to M. stadtmanae, we used qRT-PCR to analyze the expression of type I and 
type III IFN mRNAs in the different TLR-KO cell lines after 8 h stimulation with 
M stadtmanae. In TLR7-/- cells, only IFN-β showed a slight reduction in expression compared 
to the levels in WT stimulated monocytes (Figure 2E), whereas expression of genes encoding 
all three IFNs, IFN-α14, IFN-β and IFN-λ1, were significantly reduced from WT levels in 
TLR8-/- cells, and an even stronger effect was detected in double-KO cells (Figure 2E). These 
data demonstrated that not only pro-inflammatory cytokines such as TNF-α and IL-1β but also 
type I/III IFNs are induced by activation of TLR8 (and to a minor degree TLR7) with 
M. stadtmanae. 
As mice and humans differ in their repertoire of RNA-specific TLRs (171), we also 
analyzed the cytokine response of bone marrow-derived dendritic cells (BMDCs) from different 
knockout mice after stimulation with M. stadtmanae (Figure S5). Using these cells, we 
demonstrated that in mice, the recognition of this archaeon is completely dependent on mTLR7, 
whereas the absence of mTLR8 or mTLR13 had no effect on the secretion of IL-6.  
 
3.3 M. stadtmanae induces the secretion of IL-1β via activation of the 
NLRP3 inflammasome 
Maturation and release of IL-1β along with that of the pro-inflammatory cytokine IL-18, 
occurs upon activation of caspase-1, following activation of the inflammasome and recruitment 
of apoptosis associated speck-like protein containing a CARD (ASC) in response to PRR 
signaling. Inflammasomes are cytosolic multiprotein complexes that differ in their utilization 
of receptor proteins such as NLRP3 or AIM2 (165). To clarify the process of IL-1β release and 
inflammasome activation induced by M. stadtmanae, we first analyzed the release of active 
caspase-1 p20 and mature IL-1β p17 in the supernatant of human monocytes using 
immunoblotting. After stimulation for 18 h with M. stadtmanae, caspase-1 p20 and IL-1β p17 
were detected in the supernatant of both primary human monocytes (Figure 3A) and BLaER1 
monocytes (Figure 3B), indicative of inflammasome activation in both these cell types. To 
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Figure 2. M. stadtmanae induces cytokine responses in BLaER1 monocytes through TLR7 and TLR8.  
(A) Secretion of TNF- IL-1 and RANTES (CCL5) in the supernatants of BLaER1 WT and UNC93B1-/- 
monocytes as measured by ELISA. Cells were stimulated with 107 cells of M. stadtmanae, 50 ng/ml LPS or 
5 µg/ml R848 for 18 h. (B) Secretion of TNF- and IL-1 in the supernatants of BLaER1 WT and MyD88-/- or 
TRIF-/- monocytes stimulated as in (A). (C) TNF- and IL-1 secretion in the supernatants of BLaER1 WT, TLR7-
/-, TLR8-/- or TLR7-/-×TLR8-/- monocytes stimulated for 18 h with either 107 cells of M. stadtmanae, 50 ng/ml 
LPS, or 5 µg/ml of either R848, CL264, and TL8-506. (D) Secretion of TNF- and IL-1 secretion in the 
supernatants of BLaER1 WT, TLR7-/-, TLR8-/- or TLR7-/-×TLR8-/- monocytes stimulated for 18 h with 107 cells of 
M. stadtmanae or 5 µg/ml RNA purified from M. stadtmanae and complexed to DOTAP. In (A-D), ns: not 
significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 (repeated measures two-way ANOVA with 
Bonferroni post hoc test). The data from one representative clone of two are shown as the mean ± SEM of at least 
three independent experiments (n = 3-4). (E) The expression of genes encoding IFN-14, IFN- and IFN-1 in 
BLaER1 WT and TLR7-/-, TLR8-/- or TLR7-/-×TLR8-/- monocytes after stimulation with M. stadtmanae, 50 ng/ml 
LPS, or 5 µg/ml R848 for 8 h was measured by qRT-PCR. The expression ratios of all three IFN genes to the 
reference gene HPRT are shown as n-fold induction relative to the unstimulated control. ns: not significant, ** 
P≤0.01, *** P≤0.001, **** P≤0.0001 (repeated measures two-way ANOVA with Bonferroni post hoc test in (A) 
and Dunnett post hoc test in (B-E)). The data are shown as the mean ± SEM of three independent experiments 
(n = 3). 
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identify the type of inflammasome that is activated by M. stadtmanae, we first determined the 
effects of specific inhibitors for caspase-1 (Ac-YVAD-cmk) and NLRP3 (MCC950) (172) upon 
the induction of pro-inflammatory cytokine responses. Both inhibitors almost completely 
abolished the release of IL-1β observed in untreated primary human monocytes (Figure 3C) 
and BLaER1 monocytes (Figure 3D) after stimulation with M. stadtmanae, though release of 
IL-6 remained unaffected by either inhibitor confirming their specificity. These findings 
demonstrated the dependency of M. stadtmanae-induced inflammasome activation on caspase-
1 and NLRP3. An equivalent observation was made for primary moDCs and PBMCs (Figures 
S6A and S6B).  
To confirm activation of the NLRP3 inflammasome by M. stadtmanae, we generated 
additional BLaER1 cell lines in which NLRP3, ASC, or caspase-1 were knocked out, and 
stimulated these cells with M. stadtmanae (Figure 3E). The results were consistent with those 
obtained using inhibitors, showing that all three molecules were required for the secretion of 
IL-1β. However, NLRP3-/- and caspase-1-/-, but not ASC-/-, cells also showed a decrease in IL-6 
secretion after stimulation with M. stadtmanae. In addition, we tested the involvement of 
NEK7, a molecule that was recently shown to be required for NLRP3 inflammasome activation 
(50). BLaER1 NEK7-/- cells also displayed a significant decrease in IL-1β secretion (Figure 3E), 
but the effect was not as strong as that in the NLRP3, ASC, and caspase-1 knockouts.  
Pyroptosis, an inflammatory form of cell death, has been reported to follow NLRP3 
inflammasome activation, and to be involved in the release of pro-inflammatory cytokines 
(165). To test whether pyroptosis was a consequence of M. stadtmanae-induced NLRP3 
activation, cell death was measured by detecting the release of lactate dehydrogenase (LDH) 
from stimulated and unstimulated BLaER1 WT and KO monocytes. BLaER1 WT cells showed 
a release of approximately 20% of the amount of LDH released by the cell lysis control after 
stimulation with M. stadtmanae. By contrast, LDH release, and thus cell death, was 
undetectable in cells lacking the inflammasome components NLRP3, ASC, caspase-1 or NEK7 
(Figure 3F), and was also absent from TLR8-/- and TLR7-/-×TLR8-/- cells (Figure 3G) indicating 
that activation of TLR8 by M. stadtmanae hence leads to induction of pyroptosis.  
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Figure 3. M. stadtmanae activates the NLRP3 inflammasome in primary and BLaER1 monocytes. 
(A, B) Immunoblotting of cell lysates and supernatants of primary monocytes (A) and BLaER1 WT monocytes 
(B) showing the activation status of caspase-1 (p20) and IL-1 (p17). Additionally, the pro-forms of both proteins, 
namely caspase-1 p45 and IL-1 p31 were analyzed in the cell lysate. Analysis of -actin was used as loading 
control. Cells were stimulated with M. stadtmanae (100:1) or 50 ng/ml LPS for 18 h. 13.4 µM nigericin was added 
where indicated for the last 2 h. Blots are shown either from one representative donor of three in (A) or as one 
representative of three independent experiments in (B) (n = 3). (C, D) The secretion of IL-6 and IL-1 in the 
supernatants of stimulated primary monocytes (C) or BLaER1 WT monocytes (D) as measured using ELISA. 
Inhibitors of NLRP3 and caspase-1 (MCC950 and Ac-YVAD-cmk, respectively) and control substances (medium 
and DMSO, respectively) were added 1 h before stimuli were added. Cells were stimulated with 107 cells of 
M. stadtmanae, 50 ng/ml LPS, or 5 µg/ml R848 for 18 h. ns: not significant, * P≤0.05, ** P≤0.01, *** P≤0.001, 
**** P≤0.0001 (repeated measures two-way ANOVA with Tukey post hoc test). The data from at least three 
different donors in (C) (n = 3-4) or three independent experiments in (D) (n = 3) are shown as the mean ± SEM. 
(E) The secretion of IL-6 and IL-1 in the supernatants of stimulated primary monocytes or BLaER1 WT and KO 
monocytes (as indicated in the figure) was measured using ELISA. Cells were stimulated with 107 cells of 
M. stadtmanae, 50 ng/ml LPS, or 5 µg/ml R848 for 18 h. ns: not significant, * P≤0.05, *** P≤0.001, 
**** P≤0.0001 (repeated measures two-way ANOVA with Dunnett post hoc test). The data from one 
representative clone of two (except for NLRP3) of three independent experiments (n = 3) are shown as the mean 
± SEM. (F, G) Detection of LDH in the supernatant of stimulated BLaER1 WT and KO monocytes (as indicated 
in the figure). Cells were stimulated with 107 cells of M. stadtmanae, 50 ng/ml LPS, or 5 µg/ml R848. ns: not 
significant, * P≤0.05, **** P≤0.0001 (repeated measures two-way ANOVA with Dunnett post hoc test). The data 
from one representative clone of two (except for NLRP3) of three independent experiments (n = 3) are shown as 
the mean ± SEM. 
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3.4 M. stadtmanae induces the secretion of IL-1β without the formation of 
ASC specks in BLaER1 monocytes 
Several pathways for inflammasome activation have previously been described, 
including canonical, non-canonical, and alternative activation. They differ in terms of the 
stimuli responsible, and the formation of ASC specks: in particular, alternative activation in 
response to LPS stimulation and TLR4 signaling was recently shown to be independent of ASC 
speck formation (60) otherwise characteristic of both canonical and non-canonical 
inflammasome activation. To distinguish which of these activation pathways was induced upon 
stimulation of human monocytes by M. stadtmanae, we examined whether ASC specks could 
be observed in these cells. As expected, ASC speck formation was detectable in control 
BLaER1 cells treated with LPS and nigericin for 4 h to induce canonical inflammasome 
activation (Figure 4A). Conversely, in cells treated with LPS alone, which induces the 
alternative activation pathway, ASC specks were absent both 4 and 18 h after treatment 
(Figure 4A). Although we were able to show TLR8-dependent induction of pyroptosis in 
BLaER1 monocytes, usually a hallmark of canonical activation, cells stimulated with 
M. stadtmanae showed no ASC speck formation, a phenotype more comparable to that of cells 
stimulated with LPS alone and alternative activation. Secretion of IL-1β in BLaER1 monocytes 
after 4 h with M. stadtmanae or LPS alone was relatively weak (Figure 4B), however, by 18 h, 
the level of IL-1β secreted by these cells was much higher and comparable to that induced by 
canonical inflammasome activation, despite the lack of formation of ASC specks. Taken 
together, these results demonstrated that M. stadtmanae triggers a TLR8-dependent NLRP3 
inflammasome activation pathway in human monocytes that shares characteristics of canonical 
as well as alternative inflammasome activation. 
 
4 Discussion 
Only recently have researchers begun to appreciate the full diversity of our microbiome 
and to include genetic data from other domains (94). Due to methodological challenges (101), 
the function and influence of archaea on the human immune system have yet to be determined 
and, the exact mechanism by which M. stadtmanae induces inflammation remains unknown. 
Though much is known of the molecular interactions involved in bacterial-induced 
inflammation, these findings are not immediately applicable to the detection of archaea by 
immune cells: bacteria and archaea are genetically and structurally different. In particular, the 
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Figure 4. M. stadtmanae does not induce formation of ASC specks in BLaER1 monocytes. 
(A) Confocal microscopy was used to visualize fixed BLaER1 monocytes stained with ASC-specific antibodies 
(red). Cells were stimulated for 4 or 18 h with 107 cells of M. stadtmanae or 100 ng/ml LPS. LPS/nigericin 
stimulation was performed for 4 h, with 13.4 µM nigericin being added 3 h after initial LPS stimulation. After 
fixation, cells were stained with anti-ASC antibodies. DNA was stained with Hoechst 33342 (blue), and 
cytoplasmic GFP expression is shown in green. White arrowheads depict ASC specks. Scale bars: 10 µM. The 
data are shown from one representative of three independent experiments (n = 3). (B) The secretion of IL-1, IL-6 
and TNF- from cells shown in (A) was measured using ELISA. Values are compared to those obtained using 
LPS/nigericin stimulation. ns: not significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 (one-way 
ANOVA with Dunnett post hoc test). The data are from three independent experiments (n = 3) and shown as the 
mean ± SEM. 
various archaeal cell wall structures and membrane lipids are very different from those of 
bacteria (e.g., the methanoarchaea M. stadtmanae and Methanobrevibacter smithii do not 
engage NOD2, TLR2, or TLR4 (114)), and their translation and transcription machineries 
resemble eukaryotic processes (98). Here, we describe for the first time the key archaeal 
MAMP, in the form of M. stadtmanae RNA which is recognized by human immune cells 
through TLR8 and, to a lesser extent, through TLR7.  
We consider activation of human myeloid cells by M. stadtmanae to be reminiscent of 
antiviral characteristics, as it induces the gene expression of type I and type III IFNs and the 
translocation of IRF1 and IRF5 into the nucleus. The cytokine response is completely dependent 
on MyD88 and UNC93B1 but not on TRIF - these findings indicate the involvement of nucleic 
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acids, specifically ssRNA, in the recognition process. We clearly demonstrate that archaeal 
RNA, but not DNA, can induce a pro-inflammatory response. Recently, there has been great 
interest in bacterial RNA as a potent MAMP sensed by TLR7 (173, 174) and TLR8 (175, 176) 
in human immune cells. The activation of these receptors through bacterial RNA leads to 
secretion of pro-inflammatory cytokines and type I IFNs, such as IFN-α and IFN-β (31). 
Archaeal RNA activates immune cells in a similar manner and irrespective of the rRNA species. 
This observation is consistent with the recently unraveled crystal structures and binding 
mechanisms of TLR7 (177) and TLR8 (178), as both receptors bind to the degradation products 
of RNA. In contrast to murine TLR13, which binds to a specific sequence in bacterial 23S 
rRNA (179), the activation of TLR7 and TLR8 is rather sequence-independent. Both receptors 
concurrently recognize single nucleotides and short oligonucleotides (2-3mers), which should 
be present in all fractions of RNA from M. stadtmanae. This mechanism appears to be 
promiscuous and capable of recognizing a wide range of organisms, thus, it is not restricted to 
bacteria but likely involved in the recognition of viruses, and presumably other archaeal species 
besides M. stadtmanae. In BLaER1 monocytes, the recognition of M. stadtmanae is mediated 
primarily by TLR8 and to a lesser extent by TLR7. Notably, the induction of IFN-α14 and 
IFN-λ1 as well as the secretion of IL-1β is fully dependent on TLR8. This difference in receptor 
involvement might be due to the unequal expression of the two receptors, as TLR8 rather than 
TLR7 seems to be the predominant receptor in human monocytes (180). Additionally, TLR8 
and TLR9 seem to outperform TLR7 in terms of UNC93B1-mediated trafficking to the 
endosomes (181), which may explain the stronger influence of TLR8 on M. stadtmanae-
induced secretion of TNF-α and IL-6. 
We demonstrated that in addition to inducing pro-inflammatory cytokines and IFNs, 
M. stadtmanae also potently activates the NLRP3 inflammasome. As secretion of IL-1β is 
completely lost in NLRP3-/- cells, it clearly indicates that the NLRP3 inflammasome is the 
essential executor activated by M. stadtmanae. The contribution of other inflammasome 
complexes (e.g., in priming steps), however, cannot be completely ruled out. With the use of 
inhibitors and BLaER1 KO monocytes, we revealed that inflammasome activation is TLR8-
dependent and RNA-mediated. This process is most likely related to the activation process 
induced by bacterial RNA, which was also shown to trigger the NLRP3 inflammasome, leading 
to caspase-1 activation and the conversion of pro-IL-1β into its active form (182, 183). 
However, the process of M. stadtmanae-induced inflammasome activation differs from 
classical activation pathways, namely, canonical and non-canonical activation, which both lead 
to the formation of ASC specks and cell death after short stimulation times (184). In the case 
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of M. stadtmanae, inflammasome activation is delayed compared to classical NLRP3 activation 
(e.g., by LPS/nigericin stimulation). Furthermore, M. stadtmanae did not induce ASC speck 
formation in BLaER1 monocytes, although IL-1β was clearly present in the supernatant after 
18 h. This activation resembles the recently described process of alternative inflammasome 
activation (60). However, in contrast to this TLR4- and TRIF-dependent alternative activation, 
M. stadtmanae induces TLR8-dependent inflammasome activation and TLR8- and NLRP3-
dependent cell death, known as pyroptosis, independently of TRIF. Furthermore, we detected 
LDH release after stimulation with LPS alone. One possible explanation is that this mechanism 
is caspase-4-mediated, as Gaidt et al. used caspase-4-/- BLaER1 monocytes as control cells.  
Given that TLR8, but not TLR7, is involved in ROS production by the NADPH oxidase 
NOX2 complex in human neutrophils (185) and a relationship between the NLRP3 
inflammasome and NOX2 was previously demonstrated in relation to phagosomal acidification 
(186), we hypothesize that M. stadtmanae-induced TLR8-dependent NLRP3 activation is 
associated with the production of reactive oxygen species (ROS) (187). ROS production might 
provide a necessary signal for inflammasome activation, especially as these reactive 
intermediates can serve as a NEK7-mediated activation signal of the NLRP3 inflammasome 
(188). Thus, ROS may provide a feasible mechanism promoting M. stadtmanae-induced 
NLRP3 activation. Using BLaER1 NEK7-/- monocytes, we were able to confirm the 
involvement of NEK7 in M. stadtmanae-induced cytokine production, though this phenotypic 
loss was not as strong as that observed in cells lacking ASC, caspase-1, NLRP3 or TLR8. As a 
result, the detailed mechanism of how NEK and ROS influence NLRP3 activation will require 
further clarification. 
The findings regarding the interaction between the methanogenic archaeon 
M. stadtmanae and human immune cells indicate that archaea represent an important part of 
our microbiota. There is a great need for further investigation of human-associated archaea, if 
one considers that many inflammatory diseases are associated with both the 
inflammasome(189, 190) and the composition of the microbiota (157). As we identified 
M. stadtmanae as a strong activator of pro-inflammatory immune responses in vitro, it is 
conceivable that it could also contribute to an over-activation of the inflammasome in vivo. 
Therefore, future studies should adapt their experimental design to consider these important 
components of our microbiota and better understand the involvement of archaea in the 
development of inflammatory diseases such as IBD and lung hypersensitivity, and thus shape 
possible treatment approaches. 
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5 Materials and Methods 
Ethics approval statement 
Approval for these studies was obtained from the Institutional Ethics Committee at the 
University of Lübeck (Lübeck, Germany; Az. 12-202A) according to the Declaration of 
Helsinki. All donors gave written informed consent. 
 
M. stadtmanae growth and media 
M. stadtmanae (DSM 3091) was grown as previously described (115). Immune cell 
stimulation experiments were carried out with exponentially growing M. stadtmanae cells that 
were centrifuged at 3200 × g for 30 min, washed, and suspended in aerobic 50 mM Tris-HCl 
(pH 7.0).  
 
Isolation of archaeal RNA and DNA 
For the isolation of nucleic acids, M. stadtmanae cells were grown as previously 
described (115), harvested at 4 °C (3200 × g for 30 min) and lysed in liquid nitrogen using a 
Mikro-Dismembrator S laboratory ball mill (Sartorius) for 3 min at 1600 bpm. RNA was 
isolated by TRIzol extraction followed by DNase I treatment. DNA was isolated using the 
Wizard Genomic DNA Purification Kit (Promega) according to the manufacturer’s protocol. 
Concentration and purity were determined using the DS-11 spectrophotometer (DeNovix). 
RNA with an A260/A280 ratio ≥ 2.0 was considered as pure RNA; DNA with an A260/A280 ratio 
of approximately 1.8 was considered as pure DNA. 
The separation of ribosomal RNA fractions (5S, 16S and 23S rRNA) was carried out by 
excision of the respective fractions after agarose gel electrophoresis and subsequent purification 
using NucleoSpin Gel and PCR Clean-up Kit according to the manufacturer’s protocol 
(Macherey-Nagel). 
 
Cell culture 
Peripheral blood mononuclear cells (PBMCs) were prepared from the heparinized blood 
of donors by gradient centrifugation (141) using Biocoll (Merck). Subsequently, monocytes 
were isolated by counter-flow elutriation centrifugation(142). Monocyte-derived dendritic cells 
(moDCs) were then generated from monocytes as previously described (143). All cells were 
cultured in RPMI 1640 medium with stable glutamine supplemented with 10% FCS and 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin (P/S; all from Merck)) from now 
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on referred to as complete medium. Cells were grown and incubated in a humidified atmosphere 
of 5% carbon dioxide at 37 °C. 
 BLaER1 cells were a gift from Thomas Graf (Center for Genomic Regulation, 
Barcelona, Spain). The cells were cultured under the same conditions as the moDCs and 
maintained at a cell density between 1 × 105 – 2 × 106 cells/ml. Transdifferentiation was 
induced by cultivating 3 × 105 cells/ml for 6-7 days in complete medium with 10 ng/ml IL-3, 
10 ng/ml M-CSF (both Peprotech), and 100 nM β-estradiol (Sigma), as previously described 
(116). For stimulation, cells were re-plated in complete medium without IL-3, M-CSF, or 
β-estradiol. The process of transdifferentiation was regularly checked using standard flow 
cytometry analysis with CD19-BV421, CD11b-APC and CD14-PE antibodies (all from 
BioLegend) on a MACSQuant Analyzer 10 (Miltenyi Biotec). 
 
Cell stimulation 
PBMC and moDC were stimulated for 18 h at a cell density of 1 × 105 cells/well in a 
96-well flat-bottom plate with a total volume of 200 µl. Monocytes and BLaER1 cells were 
stimulated at a cell density of 0.25 × 105 and 0.5 × 105 cells/well, respectively. Whole cells of 
M. stadtmanae were applied at 107 cells per well, unless otherwise indicated. LPS (from E. coli 
O111, a gift from Otto Holst, Research Center Borstel) was added at a final concentration of 
50 ng/ml. R848, CL264, and TL8-506 (all from InvivoGen) were used at 5 µg/ml. Archaeal 
RNA was complexed with the liposomal transfection reagent DOTAP (Carl Roth) prior to 
stimulation at a ratio of 6.5 µl DOTAP per 1 µg RNA in 50 µl of pure RPMI 1640. Total RNA 
was added at a concentration of 5 µg/ml, and purified rRNA was added at 2.5 µg/ml. 
Three hours after the addition of RNA, 50 µl of complete RPMI 1640 was added to the cells. 
When indicated, RNA was digested using RNase A, DNase I or Proteinase K (Thermo Fisher) 
prior to complexing with DOTAP as recommended by the manufacturer. 
For the inhibition experiments, 7.5 µM MCC950, 50 µM Ac-YVAD-cmk (both Sigma-
Aldrich), 2 µM Cytochalasin D (Sigma), or 10 nM Bafilomycin A1 (Merck) was added to cells 
1 h prior to stimulation. 
 
Generation of stable knockout cell lines using CRISPR/Cas9 
Gene-specific gRNA sequences were designed using Benchling online software 
(https://benchling.com), in which off-target scores were kept as low as possible. The gRNA 
sequences that were used in this study are listed in Supplementary Table 1. The BbsI restriction 
site was used to clone ODNs (Thermo Fisher) encoding gRNA sequences into pU6-(BbsI)-
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CBh-Cas9-T2A-BFP (a kind gift from Ralf Kuehn (125); Addgene plasmid #64323) as 
previously described (123). Using the Human B Cell Nucleofector Kit and Nucleofector I 
device (program U-15; both Lonza), 1 × 106 cells were transfected with 2 µg plasmid DNA. 
Forty-eight hours after transfection, GFP+/BFP+ cells were sorted into 96-well plates 
(1 cell/well) by the Fluorescence Cytometry core unit at the Research Center Borstel using a 
FACSAria IIu (BD Biosciences). Two to three weeks after sorting, DNA from the clones was 
isolated using QuickExtract DNA Extraction Solution (Epicenter). Specific gene fragments 
were amplified using standard PCR methods and sequenced at Eurofins Genomics. The 
occurrence of InDel mutations was analyzed using the Tracking of Indels by Decomposition 
(TIDE) online software (191) (https://tide.nki.nl/). Only clones with frameshift mutations on all 
target alleles were used for further experiments. Clones were characterized using Western blot 
and/or ELISA depending on the availability of specific antibodies. The results of the 
immunoblot and TIDE analysis are shown in Figure S3A and S3B, respectively. 
 
Cytokine Measurements and LDH release assay 
The concentrations of released cytokines in the supernatants were determined after 16 h 
using commercial ELISA kits specific for hIL-1β, hIL-6, mIL-6, hTNF-α (Thermo Fisher), and 
hRANTES (CCL5) (R&D Systems). LDH release was measured using the Pierce LDH 
Cytotoxicity Assay Kit (Thermo Fisher) according to the manufacturer’s instructions. LDH 
release (%) was calculated as follows: (stimulated sample – unstimulated sample) / (lysis 
control – unstimulated sample) × 100. 
 
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
For expression analysis via qRT-PCR, 0.5 × 106 or 1 × 106 PBMCs, moDCs, or 
BLaER1 monocytes were stimulated for the indicated time periods (3, 6 and 12 h for PBMCs 
and moDCs; 8 h for BLaER1 monocytes) with M. stadtmanae cells (100:1) in a total volume 
of 0.5 or 1 ml at 37 °C. After stimulation, cells were harvested, and RNA was isolated using 
the NucleoSpin RNA Isolation Kit (Macherey-Nagel) according to the manufacturer’s 
instructions. The concentration and purity of RNA were analyzed using a DS-11 
spectrophotometer (DeNovix). Reverse Transcription of RNA into cDNA was achieved using 
SuperScript III, RNase Out, dNTPs, and oligo dT primer (all from Thermo Fisher) according 
to the manufacturer’s instructions. Quantitative PCR was performed using SYBR Green Master 
Mix on a LightCycler 480 II (both Roche). All primers were purchased from Thermo Fisher, 
and their sequences are listed in Supplementary Table 2. The following cycling conditions were 
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applied: 95 °C for 10 min, (95 °C for 10 s; 63 -58 °C for 10 s with -0.5 °C/cycle and 72 °C for 
6 s) × 45 cycles. The data were analyzed using LightCycler 480 software (v. 1.5.1) by 
calculating the ratio of the target gene expression to expression of the reference gene HPRT. 
Data were presented either as log2 ratio or as n-fold induction compared to unstimulated cells.  
 
Immunoblotting 
Human monocytes or BLaER1 cells were stimulated with M. stadtmanae at a ratio of 
1:100 in RPMI 1640 with 1% P/S (both Merck) for 18 h. LPS at 50 ng/ml was used as a control, 
and 13.4 µM nigericin (Invivogen) was added for the last 2 h. Supernatants were precipitated 
with trichloroacetic acid (1:10, Sigma), and the pellet was washed three times with acetone and 
suspended in LDS buffer (Thermo Fisher) with 5% β-mercaptoethanol (Carl Roth). Cell lysates 
were generated by direct lysis of the cells in LDS buffer with 5% beta-mercaptoethanol. To 
analyze KO clones, cell lysates from BLaER1 KO monocytes were generated in the same 
manner. Gel electrophoresis was performed using NuPage Novex 12% Bis-Tris protein gels 
(Thermo Fisher) for 45 min at 200 V, and proteins were subsequently blotted onto PVDF 
membranes (Carl Roth) for 1 h at 30 V. Membranes were blocked using Roti-Block (Carl Roth), 
and primary antibodies were added overnight at 4 °C. Caspase-1 p20 (Bally-1, 1:1000, 
Adipogen, used for detection of p45 and p20), IL-1β (D3U3E, 1:1000, used for detection of 
p31 and p17), -actin (8H10D10, 1:5000, both Cell Signaling), ASC (B-3, 1:1000, Santa Cruz 
Biotechnology), NLRP3 (Cryo-2, 1:1000, Adipogen), and NEK7 (EPR4900, 1:5000, Abcam) 
were used as primary antibodies. Goat-anti-mouse-Alexa 680 (Thermo Fisher) and goat-anti-
rabbit-IRDye 800CW (LI-COR Biosciences) were used as secondary antibodies at 1:10000 
dilution. The blots were visualized with the LI-COR Odyssey system (LI-COR Biosciences).  
 
Confocal laser scanning microscopy  
For confocal laser scanning microscopy, 105 moDC were incubated at 37 °C for 2 h on 
6 channel µ-Slide (Ibidi) and subsequently stimulated for 4 h with 107 M. stadtmanae cells. 
After fixation in 3% paraformaldehyde, primary antibodies were added at 1:100 in PBS with 
3% BSA and 0.1% saponin and incubated overnight at 4 °C. Cells were incubated with anti-
NF- B p65 (1:100, F-6), anti-IRF1 (1:100, B-1), or anti-IRF5 (1:100, H-56, all from Santa 
Cruz Biotechnology) overnight at 4 °C, followed by staining with an Alexa Fluor 488-
conjugated goat anti-mouse IgG (H+L) secondary antibody (1:300, Invitrogen). The nuclei 
were counterstained using Hoechst 33342 dye (1:3000, Life Technologies). For detection of 
ASC specks, BLaER1 cells were stimulated for 4 and 18 h, and staining was performed as 
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previously described. ASC (1:100, B-3, Santa Cruz Biotechnology) was used as the primary 
antibody, and Alexa Fluor 546-conjugated goat anti-mouse IgG (H+L) was used as the 
secondary antibody (1:300, Invitrogen). Images were captured using the TCS SP5 confocal 
microscope and LAS AF software (both from Leica). 
 
Statistical analysis 
The data were analyzed for statistical significance using a one-way or two-way ANOVA 
with a Bonferroni, Dunnett or Tukey post hoc test using Graph Pad Prism 7.02 software. 
P values ≤ 0.05 were considered to be statistically significant. 
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9 Supplementary Material 
9.1 Supplementary Figures 
 
Figure S1. M. stadtmanae DNA does not induce an immune response in human PBMCs.  
Quantification of TNF-α (left) and IL-1β (right) by ELISA of the supernatant of PBMCs either left unstimulated, 
stimulated by M. stadtmanae cells, or by purified DNA. DNA was complexed to the liposomal transfection reagent 
DOTAP and added to human PBMCs for 18 h. The data are from three different donors (n = 3) and shown as the 
mean ± SEM. 
 
 
 
 
Figure S2. Response of BLaER1 monocytes to M. stadtmanae. 
(A) Quantification of TNF-α, IL-6, and IL-1β in the supernatant of BLaER1 monocytes either left unstimulated or 
stimulated with 107 M. stadtmanae cells, 50 ng/ml LPS or 5 µg/ml R848 using ELISA. Cytochalasin D and 
Bafilomycin A (inhibitors of phagocytosis and endosomal acidification, respectively) were added 1 h prior to 
stimulation. The data from three independent experiments (n = 3) are shown as the mean ± SEM. (B) Confocal 
microscopy of BLaER1 monocytes 4 h after the addition of M. stadtmanae. GFP expression is shown in green and 
Hoechst 33342 staining in blue. White arrows indicate the points where M. stadtmanae is phagocytosed by 
BLaER1 cells. Scale bars: 10 µM. The images shown are representative examples from one of two independent 
experiments (n = 2). 
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Figure S3. Generation of BLaER1 KO cell lines. 
(A) Immunoblotting of BLaER1 KO cell lines was performed if specific antibodies were available. β-actin was 
used as the loading control. (B) Types of InDel mutations that were identified by TIDE analysis for all KO clones 
used in this study. All clones show frameshift mutations on both alleles. 
 
 
 
 
Figure S4. Response of BLaER1 TREML4-/- to M. stadtmanae and TLR7/8 agonists. 
Quantification of TNF-α and IL-6 in the supernatant of BLaER1 WT and TREML4-/- monocytes stimulated with 
107 M. stadtmanae cells, 50 ng/ml LPS or 5 µg/ml R848, CL264 or TL8-506 for 18 h using ELISA. The data from 
two independent experiments (n = 2) and two different knockout clones are shown as the mean ± SEM.  
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Figure S5. Stimulation of IL-6 secretion in response to M. stadtmanae is dependent on mTLR7 but not on 
mTLR8/mTLR13 in murine bone marrow-derived dendritic cells (BMDCs). 
(A) Quantification of IL-6 in the supernatant of wild-type (WT), TLR7-/- or TLR8-/- murine BMDCs stimulated 
for 18 h with 107 cells of M. stadtmanae, 50 ng/ml LPS, 5 µg/ml R848 as measured by ELISA. (B) Quantification 
of IL-6 in the supernatant of WT or TLR13-/- murine BMDCs stimulated for 18 h with 107 cells of M. stadtmanae, 
50 ng/ml LPS, 5 µg/ml R848 or 5 µM Sa19 (TLR13 agonist) was measured by ELISA. (A, B) ns: not significant, 
** P≤0.01, **** P≤0.00001 (two-way ANOVA with Bonferroni post hoc test). The data from two to four 
independent experiments (n = 2-4) are shown as the mean ± SEM. 
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Figure S6. Secretion of IL-1β in human moDCs and PBMCs is dependent on NLRP3 and caspase-1. 
(A, B) Secretion of IL-6 (left) and IL-1β (right) in the supernatants of stimulated human moDCs (A) and PBMCs 
(B) was measured using ELISA. Cells were treated with either MCC950 or Ac-YVAD-cmk (inhibitors of NLRP3 
and caspase-1, respectively), or control substances (medium and DMSO, respectively) 1 h prior to stimulation with 
107 cells of M. stadtmanae or 50 ng/ml LPS for 18 h. ns: not significant, * P≤0.05, ** P≤0.01, *** P≤0.001, 
**** P≤0.0001 (repeated measures two-way ANOVA with Tukey post hoc test). The data from at least three 
different donors (n = 3-5) are shown as the mean ± SEM.  
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9.2 Supplementary Tables 
 
 
9.3 Supplementary Methods 
Stimulation of murine BMDCs 
Bone marrow cells from C57BL/6 WT, TLR7-/-, TLR8-/- (both are a kind gift from Douglas 
Golenbock, UMASS, Worcester, USA), or TLR13-/- (a gift from Carsten Kirschning, University 
of Duisburg-Essen, Essen, Germany) were differentiated into BMDCs as described previously 
(176). Cells were seeded at 1 × 105 cells/ml in a 96-well plate and stimulated for 18 h with 107 
cells of M. stadtmanae, 50 ng/ml LPS, 5 µg/ml R848, or 5 µM Sa19 (both from Invivogen). 
Table S1. Guide RNA sequences 
Gene gRNA sequence (5‘-3‘) + PAM 
ASC ATGGACAGCAGCGCGCCCCG CGG 
CASP1 ACAGACAAGGGTGCTGAACA AGG 
MyD88 ACCACACTTGATGACCCCCT GGG 
Nek7 TGTGGTTGGAACTGAGGAAC AGG 
NLRP3 GTCTTCCTGGCATATCACAG TGG 
TLR7 ACTGTGTACCTATTCCACTG GGG 
TLR8 (double KO) CGTTCTGGTGCTGTACATTG GGG 
TLR8 (single KO) ACAGGAAGTTCCCCAAACGG TGG 
TREML4 A2 AAGAGTCCACATAGGAGACG TGG 
TREML4 D1 AGCCAGGGAAGAGTCCACAT AGG 
TRIF GATGAGGCCCGAAACCGGTGT GGG 
UNC93B1 CTACGACGAGACCTACCGCG AGG 
Table S2. Primer for qRT-PCR 
Gene Name Sequence (5‘-3‘) Reference 
IFNL1 
(IFN-λ1) 
huIFN-L1-fw CGCCTTGGAAGAGTCACTCA 
(192) 
huIFN-L1-rv GAAGCCTCAGGTCCCAATTC 
IFNA14 
(IFN-α14) 
huIFN-a14-fw AGGAGGAATTTGATGGCAAC 
(193) 
huIFN-a14-rv AGCAGCAGATGAGTTCTTTG 
IFNB1 
(IFN-β) 
huIFN-b-fw AAGCAGCAATTTTCAGTGTCAG  
huIFN-b-rv CCTCAGGGATGTCAAAGTTCA  
HPRT 
huHPRT_fw GTCAGGCAGTATAATCCAAAGA  
huHPRT_rv GGGCATATCCTACAACAAACT  
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VI Additional Results 
1 Materials and Methods 
This section offers additional materials and methods that were not mentioned in chapters IV or 
V before. If not indicated otherwise, experiments were performed as described in these sections. 
 
Cell stimulation 
Besides the different stimuli described in chapters IV and V, cells have been additionally 
stimulated with Lactococcus lactis or the lipopeptide Pam3CSK4 (EMC microcollections) 
where indicated. L. lactis has been prepared as described by Stein, et al. (176) and added in a 
final load of 107 bacteria/ml. Pam3CSK4 has been used in a final concentration of 10 µM. 
 
Cell Stimulation with extracellular potassium 
To investigate the influence of potassium efflux on IL-1β secretion, potassium chloride (KCl) 
was added to the medium before stimulation. Briefly, primary monocytes or BLaER1 
monocytes were seeded into a 96-well plate (0.25 × 105 cells/well or 0.5 × 105 cells/well, 
respectively) and incubated for 2 h. Different concentrations of KCl (Sigma) from a 2 M stock 
ranging from 1 mM to 50 mM were added to cells and incubation was continued for about 1 h. 
107 cells of M. stadtmanae, 50 ng/ml LPS, 5 µg/ml R848 or 10 µM Pam3CSK4 were added and 
cells were stimulated for 18 h in a total volume of 200 µl. For the last 2 h of stimulation, 
13.4 µM nigericin (Invivogen) was added where indicated. Concentration of IL-1β and IL-6 in 
the supernatant was analyzed by ELISA (see chapter V.5) 
 
Generation of BLaER1 KO cell lines 
BLaER1 KO cells were generated as described in chapter V.5. In addition, genes for Cathepsin 
B, GSDMD, MAVS, RIG-I and STING were knocked out using the CRISPR/Cas9 system. 
Specific gRNAs for each gene are listed in Table VI-1. Confirmation of successful KOs was 
done using TIDE analysis (IX.1) and for MAVS-/-, RIG-I-/- and STING-/- additionally by 
immunoblotting. αRIG-I (D12, 1:200, Santa Cruz), αMAVS (E-3, 1:200, Santa Cruz) and 
αSTING (clone # 723505, 1:2500, R&D systems) have been used. 
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Generation of a BLaER1 ASC-mScarlet reporter cell line via homology directed repair 
(HDR) 
The red fluorescent protein mScarlet (194) was c-terminally linked to endogenous ASC via a 
(G4S)3 linker peptide using the CRISPR/Cas9 system. Briefly, the gRNA sequence (5’-
AGGACCTGGAGCGGAGCTG) targeting the C terminus of the ASC gene was cloned into 
the plasmid pU6-(BbsI)-CBh-Cas9-T2A-BFP (a kind gift from Ralf Kuehn (125); Addgene 
plasmid #64323) via the BbsI restriction site as described earlier. The donor DNA was 
generated by amplification of an ASC left and right homology arm (each about 800 bp) closely 
to gRNA target site and amplification of the mScarlet gene from the pmScarlet_C1 plasmid 
(pmScarlet_C1 was a gift from Dorus Gadella (194); Addgene plasmid # 85042) with specific 
overhangs using Herculase II Fusion polymerase (Agilent). The PCR fragments were purified 
with PureLink PCR Purification kit (Thermo Fisher) and assembled together with a PCR-
amplified pUC19 plasmid to generate the HDR donor plasmid pUC19_HDR-ASC_mScarlet 
via the NEBuilder HiFi DNA Assembly Cloning kit (New England Biolabs). Plasmid integrity 
was verified by restriction digest using BamHI, EcoRI, SmaI, XbaI and NotI (all Thermo 
Fisher) according to the manufacturer’s instructions and by sanger sequencing at eurofins 
genomics. To generate the endogenous ASC-mScarlet fusion protein, BLaER1 cells were 
transfected with 1 µg of the CRISPR/Cas9 plasmid pU6-ASC-Cterm-CBh-Cas9-T2A-BFP and 
2 µg of the donor template pUC19_HDR-ASC_mScarlet by nucleofection. Two days after 
nucleofection, single cell sorting of GFP+BFP+ cells was performed by the Fluorescence 
Cytometry core facility at the Research Center Borstel. Nucleofection and cell sorting are 
already described in chapter V.5. Positive clones were identified by PCR targeting the mScarlet 
insert and verified by sequencing. The clone A7 with a heterologous insertion was selected and 
analyzed by confocal microscopy, Western Blot and ELISA (methods are described in detail in 
chapter V.5). 
  
Table VI-1. gRNA sequences for generation of BLaER1 KO cell lines. 
Gene gRNA sequence (5‘-3‘) + PAM 
CTSB (Cathepsin B) TCAACAAACGGAATACCACG TGG 
GSDMD TTGAGGGCTTCCTAACCACC AGG 
MAVS GTAGATACAACTGACCCTGT GGG 
DDX58 (RIG-I) TACCTACATCCTGAGCTACA TGG 
TMEM173 (STING) GCTGGGACTGCTGTTAAACG GGG 
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2 Results 
2.1 Involvement of cytoplasmic nucleic acid-specific receptors in 
recognition of M. stadtmanae 
While it was shown in chapter V that RNA from M. stadtmanae is mainly recognized 
by the endosomal receptors TLR7 and TLR8, the role of cytosolic nucleic acid sensors was not 
evaluated. Most immune cells and many non-immune cells possess a repertoire of different 
cytosolic nucleic acid-specific receptors. These recognition pathways include the cGAS-
STING and the RIG-I/MDA5-MAVS pathway, which detect cytosolic dsDNA or dsRNA/5’-
triphosphate RNA, respectively. It was recently shown that the cGAS-STING pathway is 
important for the response against various pathogens, including Mycobacterium tuberculosis, 
Listeria monocytogenes, Plasmodium falciparum or Neisseria gonorrhoeae (195-198). DNA 
from these pathogens becomes accessible either through lysis of the bacteria in the cytosol or 
through translocation of DNA from the phagolysosome to the cytosol.  
As it is unknown if archaeal nucleic acids are recognized in the cytosol or if potential 
archaeal cyclic dinucleotides are present that can also directly activate STING, we investigated 
the role of the cGAS-STING and the RIG-I-MAVS pathways in M. stadtmanae-induced 
immune cell activation. To address this question, we generated clonal BLaER1 cell lines 
deficient for STING, RIG-I or MAVS using the CRISPR/Cas9 system. Three different clones 
for each gene knockout were verified by TIDE analysis (IX.1) and by Western Blot (Figure VI-
1 A-C). As it was recently shown that the cGAS-STING pathway has the potential to activate 
the NLRP3 inflammasome in human monocytes (38), we first stimulated BLaER1 monocytes 
with M. stadtmanae and analyzed the secretion of IL-1β and IL-6 in the supernatant (Figure VI-
1 D; results for all clones are shown in Figure IX-1). Neither disruption of the cGAS-STING 
pathway nor the RIG-I- and MAVS-dependent pathways did result in a significant decrease in 
IL-1β or IL-6 release. This leads to the suggestion that M. stadtmanae -induced inflammasome 
activation is independent of the STING pathway. 
One of the major function of cytosolic nucleic acid receptors is the induction of type I 
IFNs. To clarify the role of cGAS-STING and RIG-I-MAVS pathways in induction of IFNs by 
M. stadtmanae, BLaER1 STING-/-, RIG-I-/- and MAVS-/- monocytes have been stimulated with 
M. stadtmanae and induction of IFN-β expression has been measured via qRT-PCR (Figure VI-
1 E; results for all clones are shown in Figure IX-1). The specificity of the different clones was 
determined by stimulation with pathway-specific activators, namely DNA for the cGAS-
STING pathway and 5’-triphosphate RNA for the RIG-I-MAVS pathway. Expression of IFN-β 
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after stimulation with M. stadtmanae was not reduced, neither in the STING-/- nor in the 
RIG-I-/- and MAVS-/- BLaER1 monocytes. Altogether, these results demonstrate that induction 
of cytokine secretion and IFNs by M. stadtmanae is independent of major cytosolic nucleic acid 
recognition pathways. 
 
Figure VI-1. Response to M. stadtmanae is independent of major cytosolic nucleic acid recognition pathways. 
(A-C) Immunoblotting of BLaER1 KO cell lines (STING, RIG-I and MAVS) was performed using specific 
antibodies for each target gene. Three different clones per gene KO were analyzed. β-actin was used as the loading 
control. (D) IL-1β and IL-6 secretion in the supernatants of BLaER1 WT, STING-/-, RIG-I-/- or MAVS-/- monocytes 
stimulated for 18 h with either 107 cells of M. stadtmanae, 50 ng/ml LPS, or 5 µg/ml R848 was measured by 
ELISA. (E) The expression of IFN-β in BLaER1 STING-/-, RIG-I-/- or MAVS-/- monocytes after stimulation with 
M. stadtmanae (100:1), 0.5 µg/ml 5’-ppp-RNA, or 1 µg/ml plasmid DNA for 6 h was measured by qRT PCR. The 
expression ratios of IFN-β gene to the reference gene HPRT are shown as log2 n-fold induction relative to the 
unstimulated control cells. (D-E) ns: not significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 (repeated 
measures two-way ANOVA with Dunnett post hoc test). The data are shown as the mean ± SEM of four 
independent experiments (n=4) in (D) or three independent experiments (n = 3) in (E) from one representative 
clone per gene. Three different STING-/- clones and two different clones of each RIG-I-/- and MAVS-/- were used 
in qRT-PCR and ELISA (Figure IX-1). 
2.2 Role of cathepsin B and gasdermin D on cytokine response to 
M. stadtmanae 
We clearly demonstrated that recognition of M. stadtmanae takes place in the 
phagolysosome and is mediated through the RNA-specific receptors TLR7 and TLR8. Yet, it 
is unclear how M. stadtmanae activates the NLRP3 inflammasome. A role in lysosomal-
dependent NLRP3 inflammasome activation was assigned to cathepsin B (CatB), a cysteine 
protease important for proteolytic functions in the cytosol (199, 200). Furthermore, it was 
shown that CatB is important for TLR8-dependent inflammasome activation induced by HIV 
using CA-074-Me as inhibitor of CatB (187). Based on these publications, a role for CatB in 
M. stadtmanae-induced NLRP3 activation was suggested. Accordingly, a CatB-deficient 
BLaER1 cell line has been generated using the CRISPR/Cas9 system. The cell line was 
analyzed for frameshift mutations using TIDE analysis (IX.1). To examine the role CatB, we 
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stimulated BLaER1 WT and CatB-/- monocytes with M. stadtmanae and measured secretion of 
IL-1β and IL-6 (Figure VI-2). Stimulation of CatB-/- cells with M. stadtmanae results in 
cytokine secretion levels comparable to WT cells. This leads to the conclusion that CatB is 
dispensable for recognition of M. stadtmanae and inflammasome activation induced by this 
archaeon. However, a reduction of IL-1β is detectable after stimulation with LPS. The role of 
CatB in LPS-induced alternative inflammasome activation was not yet evaluated but it was 
shown that CatB an important factor for canonical inflammasome activation in THP-1 
monocytes through LPS/nigericin (201). Nevertheless, all studies on CatB using the inhibitor 
CA-074-Me should be looked at critically because CA-074-Me not only inhibits CatB but rather 
a wide range of different cathepsins and cystatins (202). However, a role of CatB in 
M. stadtmanae- or TLR8-induced inflammasome activation in BLaER1 monocytes could not 
be observed. 
 
Figure VI-2. Response to M. stadtmanae is independent of Cathepsin B. 
IL-1β and IL-6 secretion in the supernatants of BLaER1 WT or CatB-/- monocytes stimulated for 18 h with either 
107 cells of M. stadtmanae, 50 ng/ml LPS, or 5 µg/ml of R848 is shown. ns: not significant, ** P≤0.01 (repeated 
measures two-way ANOVA with Bonferroni post hoc test). The data are shown as the mean ± SEM of four 
independent experiments (n=4).  
In addition to the pro-inflammatory cytokines pro-IL-1β and pro-IL-18, GSDMD is an 
additional target that is cleaved and activated by caspase-1. After cleavage of GSDMD, the N-
terminal fragment oligomerizes into the cell membrane, where it forms a pore-like structure. 
These pores impair the cell integrity which can lead to pyroptosis, an inflammatory form of 
programmed cell death (54). However, it has been recently discovered that GSDMD pores can 
also function as channels for IL-1β to passively leave the cell without induction of pyroptosis 
(55). So far, the role of GSDMD has only been described for canonical and non-canonical 
inflammasome activation. It is unclear if GSDMD is necessary for the secretion of IL-1β after 
alternative inflammasome activation. Since M. stadtmanae- and TLR8-dependent 
inflammasome activation resemble key characteristics of alternative activation, the function of 
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GSDMD in these pathways is also unknown. To investigate the role of GSDMD in 
M. stadtmanae-induced inflammasome activation, BLaER1 GSDMD-/- monocytes were 
generated using CRISPR/Cas9. Positive KO clones have been selected based on TIDE analysis 
(IX.1). Stimulation of GSDMD-/- cells with CL097 or LPS/nigericin leads to a decreased release 
of IL-1β and LDH with only minor effects on IL-6 secretion (Figure VI-3; results for all clones 
are shown in Figure IX-2). As both stimuli are activators of the canonical inflammasome 
activation pathway, GSDMD is important for IL-1β release and induction of pyroptosis, which 
we could reproduce in our experiments. In contrast, stimulation with LPS or M. stadtmanae did 
not lead to a reduction in IL-1β or LDH release from these cells and we suggest that GSDMD 
is negligible in alternative inflammasome activation. Yet, IL-1β secretion in GSDMD-/- cells 
was largely impaired after stimulation of R848. As R848 should not trigger canonical activation 
(188), the role of GSDMD in this setting is ambiguous. Although our results demonstrate that 
GSDMD is dispensable for alternative and M. stadtmanae-induced inflammasome activation, 
the mechanism of how IL-1β is able to exit the cells without GSDMD pores is still unresolved.  
 
Figure VI-3. Inflammasome activation and LDH release are independent of GSDMD. 
(A) IL-1β and IL-6 secretion and (B) release of LDH in the supernatants of BLaER1 WT or GSDMD-/- monocytes 
stimulated for 18 h with either 107 cells of M. stadtmanae, 5 µg/ml of CL097 5 µg/ml R848 or 50 ng/ml LPS is 
shown. ns: not significant, * P≤0.05, ** P≤0.01, **** P≤0.01 (repeated measures two-way ANOVA with 
Bonferroni post hoc test). The data are shown as the mean ± SEM of four independent experiments (n=4). Data 
from one of three different clones are shown (Figure IX-2). (LDH, lactate dehydrogenase; nig, nigericin) 
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2.3 Influence of Potassium Efflux on Inflammasome Activation Induced by 
M. stadtmanae 
In case of canonical NLRP3 inflammasome activation, efflux of potassium ions from 
the cell is a trigger that is shared between most canonical activators (47) with a few exceptions 
including imiquimod and CL097 (188). If a NLRP3 activator is dependent on potassium efflux, 
the secretion of IL-1β can be inhibited by addition of high concentrations of KCl into the 
surrounding medium (59). To investigate the influence of potassium efflux on M. stadtmanae-
induced NLRP3 inflammasome activation, primary human monocytes were stimulated with 
M. stadtmanae in medium containing increasing concentrations of KCl. Compared to canonical 
activation (LPS + nigericin or Pam3CSK4 + nigericin) where a solid inhibition of IL-1β 
secretion with increasing concentrations of KCl is detectable, the effect on IL-1β secretion after 
stimulation with M. stadtmanae is weaker (Fig. VI-4). Similar effects were observed after 
stimulation with LPS or R848. Like the alternative activation pathway, IL-1β secretion from 
monocytes cannot be inhibited by extracellular KCl after stimulation with M. stadtmanae. Thus, 
potassium efflux is not required for M. stadtmanae-induced inflammasome activation. 
 
 
Figure VI-4. Secretion of IL-1β in primary monocytes after stimulation with M. stadtmanae is independent 
of potassium efflux. 
(A-C) Primary human monocytes were stimulated in medium with increasing concentrations of KCl up to 25 mM. 
107 cells of M. stadtmanae, 5 µg/ml R848, 50 ng/ml LPS or 10 µM Pam3CSK4 were added for 18 h and 13.4 µM 
nigericin were added for the last 2 h where indicated. Concentration of IL-1β and IL-6 were measured by ELISA 
and are depicted as absolute concentration in (A) or relative concentration in (B). Release of LDH into the 
supernatant is shown in (C). In (A-C), the data shown are the mean ± SEM of at least three different donors 
(n = 3-4). (LDH, lactate dehydrogenase; nig, nigericin) 
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2.4 Characterization of ASC-mScarlet BLaER1 reporter cell line 
Inflammasome activation induced by M. stadtmanae in BLaER1 monocytes does not 
induce the formation of ASC specks as shown in chapter V. In order to simplify visualization 
of ASC speck formation and to allow live cell imaging, we generated an ASC reporter cell by 
fusion of a red fluorescent protein mScarlet to the C-terminus of endogenous ASC in BLaER1 
cells via a (G4S)3 linker peptide. The gene encoding mScarlet was cloned into a pUC19 plasmid 
with approx. 800 bp homology arms on each site and the linker peptide at the N-terminus of 
mScarlet. This plasmid served as donor DNA for HDR in BLaER1 cells using the 
CRISPR/Cas9 system. Single cell clones were analyzed by PCR and the clone A7 was obtained 
which is heterozygous for the ASC-mScarlet fusion protein. The heterogenicity should ensure 
a proper formation and activation of the inflammasome as mScarlet could possibly interfere in 
speck formation. Initially, the clone A7 was analyzed by Western Blot (Figure VI-5 A) showing 
that this clone expresses WT ASC as well as the ASC-mScarlet fusion protein in comparable 
amounts. Confocal microscopy confirmed that the ASC-mScarlet protein in clone A7 is 
functional as red fluorescence of mScarlet is detectable in all cells. The clone also shows GFP 
expression as well as a similar morphology compared to WT BLaER1 monocytes 
(Figure VI-5B). The reporter cell line was stimulated with M. stadtmanae, LPS and different 
TLR7/8 stimuli to ensure that the cells secrete similar cytokine levels of TNF-α, IL-6 and IL-1β 
compared to WT cells and to show that inflammasome activation is not disturbed 
(Figure VI-5C). The results clearly demonstrate that the reporter cell line is still capable of 
inflammasome activation and has no defects in cytokine secretion. 
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Fig VI-5. BLaER1 ASC reporter cell line A7 shows heterozygous expression of an ASC-mScarlet fusion 
protein with cytokine secretion levels comparable to WT cells. 
(A) Immunoblotting of cell lysates from BLaER1 WT and ASC-mScarlet A7 monocytes showing the expression 
of ASC (22 kDa) and ASC-mScarlet fusion protein (49 kDa). Analysis of -actin (49 kDa) was used as loading 
control. (B) BLaER1 WT and ASC-mScarlet A7 monocytes were analyzed by confocal microscopy. Brightfield 
as well as emission of GFP (green) and mScarlet (red) was measured. Scale bars represent 25 µm. (C) The secretion 
of TNF-α, IL-6 and IL-1 in the supernatants of stimulated BLaER1 WT and ASC-mScarlet A7 monocytes was 
measured using ELISA. Cells were stimulated with 107 cells of M. stadtmanae, 50 ng/ml LPS, 5 µg/ml R848, 
CL097, CL264 or TL8-506 for 18 h. ns: not significant (repeated measures two-way ANOVA with Bonferroni 
post hoc test). The data of three independent experiments (n = 3) are shown as the mean ± SEM. (BF, brightfield; 
GFP, green fluorescent protein) 
To demonstrate functional ASC speck formation in the ASC-mScarlet cell line, the cells 
were pre-incubated with LPS and the canonical inflammasome activation was then induced by 
addition of nigericin. As the reporter cell line can be used for live cell imaging, images were 
taken every thirty seconds after addition of nigericin. Images for the first 18 minutes in 6-minute 
steps are shown and demonstrate that nigericin is a fast inducer of inflammasome activation as 
ASC specks are detectable already after 12 minutes (Figure VI-6A). Two hours after addition 
of nigericin, ASC specks are clearly formed in many cells (Figure VI-6B). In contrast, to 
LPS/nigericin stimulation, unstimulated cells show a largely uniform distribution of ASC in 
cytosol (Figure VI-6C). Stimulation of ASC-mScarlet cells with M. stadtmanae did not lead to 
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formation of ASC specks which is consistent with the results in chapter V. Furthermore, 
stimulation with R848 or LPS did also not induce formation of ASC specks confirming that 
alternative inflammasome activation is independent of ASC specks. Our results confirm that 
the ASC-mScarlet reporter cell line (clone A7) can be used as a functional reporter cell line to 
detect ASC speck formation in live cell imaging.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig VI-6. M. stadtmanae does not induce ASC speck formation in a BLaER1 ASC reporter cell line. 
(A, B) BLaER1 ASC-mScarlet A7 monocytes were pre-incubated for 3 h with 50 ng/ml LPS before 13.4 µM 
nigericin has been added. Cells were analyzed directly after addition of nigericin via live cell confocal microscopy 
in (A) or after 2 h in (B). (C) BLaER1 ASC-mScarlet A7 monocytes were stimulated with M. stadtmanae (100:1), 
5 µg/ml R848 or 50 ng/ml LPS for 16 h and analyzed by confocal microscopy. (A-C) Brightfield as well as 
emission of GFP (green) and mScarlet (red) was measured. Scale bars represent 10 µm in (A) or 25 µm in (B, C). 
White arrowheads indicate ASC specks. Representative micrographs from one of two independent experiments 
are shown.  
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VII General Discussion 
In the last decade, several studies have shown that the microbiota has a great impact on 
our health and homeostasis. Yet, most of these studies are limited to the bacterial diversity and 
largely ignore other organisms such as fungi, viruses, and archaea. Particularly archaea have 
been neglected by medical microbiology. Important reasons for this are methodological 
limitations as it has been recently shown that so-called ‘universal’ primer for 16S rRNA 
sequencing, which should amplify both bacterial and archaeal rRNA, are largely biased towards 
bacteria. In addition, DNA isolation methods and data analyses are often not optimized for the 
detection of archaea. It is to be assumed that the true diversity of the archaeome is extensively 
underestimated (100-102).  
Already in 2003, the potential existence of archaeal pathogens was discussed by 
Cavicchioli, et al. (203). Although a high diversity of archaea lives in close contact to humans, 
no pathogenic archaea have been identified by now. The apparent lack of pathogenic archaea 
contributes to the fact that archaea are widely overlooked as members of our microbiota. 
Nevertheless, several studies suggest a role of archaea in different diseases, yet exact 
mechanisms of how archaea might influence disease manifestation and progression are 
unknown (104, 106, 107, 111, 113). This thesis is focused on the interaction of two distinct 
archaeal gut inhabitants with the human innate immune system. On the one hand 
M. luminyensis, an archaeon that might provide the host with benefits as it is able to degrade 
TMA (133), on the other hand M. stadtmanae which is able to induce strong immune response 
in human myeloid cells (114) and which is potentially associated with IBD (111). In the 
following sections (I) the immune response of M. luminyensis and its benefits for the host, (II) 
the detailed molecular mechanisms of recognition of M. stadtmanae and (III) its ability to 
activate the inflammasome are discussed. Furthermore, (IV) possible other recognition 
mechanisms of archaea and (V) the potential disease association of M. stadtmanae and major 
implications of this study will be discussed. 
1 Immune response to M. luminyensis – Is its application as archaebiotic 
reasonable? 
Methanomassiliicoccales describes a new order of methanogenic archaea of which three 
species have been associated with the human microbiota, namely Candidatus 
Methanomethylophilus alva Mx1201, Canditatus Methanomassilliicoccus intestinalis Mx1, 
and M. luminyensis, which has been part of this study (155). These archaea have unique 
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metabolic functions as they are able to use methylamines as substrates for methanogenesis. In 
contrast, M. smithii or M. stadtmanae, the two other important methanogenic gut inhabitants, 
cannot utilize methylamines. Due to their ability to degrade the methylamine TMA, 
Methanomassiliicoccales have been discussed as beneficial organisms for the host (103). TMA 
itself is produced by gut bacteria and can be converted into TMAO by the liver. It is assumed 
that TMAO is associated with the development of atherosclerosis, cardiovascular disease, and 
chronic kidney disease (155, 204). Therefore, Methanomassiliicoccales could be supplemented 
as living organisms, a so-called archaebiotic (103), to convert TMA into methane, thereby 
lowering the amount of TMAO in the body. Other, maybe harmful effects of these archaea on 
the host and particularly on the immune system, have not been evaluated before. This study is 
focused on the AMP susceptibility of M. luminyensis and the innate immune response against 
this archaeon. 
We demonstrated that the sensitivities of M. luminyensis against three AMPs, namely 
LL32, NK2, and Lpep19.2-5, are comparable to those of M. stadtmanae. Although, both 
archaea are less sensitive to these AMPs compared to M. smithii, the MIC is still in a low 
micromolar range. Thus, the population of M. luminyensis can probably be controlled by the 
immune system and IECs through secretion of AMPs to prevent overgrowth. Moreover, we 
analyzed the pro-inflammatory response of human PBMCs and moDCs after stimulation with 
M. luminyensis. In comparison to M. stadtmanae, M. luminyensis induces only a weak secretion 
of TNF-α and IL-1β. The levels of secreted cytokines rather resemble the amounts induced by 
M. smithii (111, 114). Interestingly, the mild immune response against M. luminyensis 
correlates with the low phagocytotic activity of moDCs on this archaeon. If we assume that 
M. luminyensis is also recognized intracellularly, the low phagocytosis probably accounts for 
the low levels of secreted cytokines. The phagocytosis rate of M. smithii has not been quantified 
by Bang, et al. (114), yet CSLM and transmission electron microscopy (TEM) micrographs 
from this study clearly show that it is apparently less phagocytosed compared to M. stadtmanae. 
Overall, M. luminyensis is susceptible to AMPs and induces at the same time only a weak 
immune response. These features are favorable for application as an archaebiotic because the 
growth of M. luminyensis can be controlled through AMPs while excessive release of pro-
inflammatory cytokines, which could lead to inflammation and cell damage, has not been 
observed. Our in vitro study does not reveal any concerns for the usage of M. luminyensis as 
TMA degraders in humans, however, more studies including in vivo experiments are urgently 
needed to confirm its safety and to exclude harmful effects of M. luminyensis on humans. 
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2 RNA as key MAMP of M. stadtmanae 
It has been shown by various studies that M. stadtmanae activates the immune system 
in vitro and in vivo with a pro-inflammatory phenotype (111-114, 205). Thereby, the observed 
immune activation is considerably stronger compared to other known methanogenic gut 
inhabitants M. smithii (111, 114) and M. luminyensis (this study, chapter IV). Although plenty 
is known about the function of PRRs and their respective microbial ligands, the molecular 
mechanism of how M. stadtmanae is recognized remained elusive. Since archaea utilize 
structural components which are different from those of bacteria and eukaryotes, archaeal cell 
wall structures like pseudomurein or heteropolysaccharides have been discussed as potential 
MAMPs (98). This study shows that the response of human PBMCs and moDCs does not only 
include release of pro-inflammatory cytokines such as IL-6 and IL-1β but is also characterized 
by nuclear translocation of IRF1 and IRF5 and increased expression of type I and III IFNs.  
By using a CRISPR/Cas9-mediated loss-of-function approach of specific receptor and 
signaling proteins in BLaER1 monocytes, we identified TLR7 and exceedingly TLR8 as key 
receptors in recognition of M. stadtmanae (Figure VII-1). Transfection of purified archaeal 
RNA into primary PBMCs and moDCs as well as BLaER1 monocytes identified RNA as the 
major MAMP. In contrast to mTLR13, hTLR7 and hTLR8 do not recognize a specific sequence 
in the 23S rRNA but are activated by small RNA fragments and degradation products (177, 
178, 206-208). This recognition model is consistent with our results as we could not observe 
significant differences in cytokine secretion levels among different rRNA species (5S, 16S and 
23S) of M. stadtmanae. Prior to this study, Bang, et al. (114) have already utilized a HEK293 
transfection system with common human TLRs (TLR2-5 and TLR7-9) as well as the 
intracellular NLRs, nucleotide-binding oligomerization domain-containing protein (NOD)1 
and NOD2, to identify PRRs that specifically recognize M. stadtmanae. However, none of these 
receptors led to IL-8 secretion from HEK293 cells after stimulation with M. stadtmanae. Since 
HEK293 are epithelial kidney cells, phagocytosis does not belong to their principal function 
unless certain proteins are artificially expressed (209). This might explain why TLR7- and 
TLR8-transfected HEK293 cells do not respond to M. stadtmanae as phagocytosis was shown 
to be essential to mount a cytokine response in moDCs (114). Therefore, the BLaER1 monocyte 
model system seems to be a more suitable model to study the function of endosomal TLRs, as 
this cell line holds monocytic key functions such as phagocytosis and lysosomal degradation of 
engulfed microbes. 
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Figure VII-1. Activation model of human monocytes by M. stadtmanae. 
M. stadtmanae is taken up by myeloid immune cells through phagocytosis. Inside the phagolysosome, the archaea 
are degraded, and archaeal RNA is released. The RNA can then be recognized by TLR7 and TLR8 and a signaling 
cascade is induced leading to the nuclear translocation of the transcription factors IRF5 and NF-κB. These 
transcription factors induce the expression of type I and III interferons as well as proinflammatory cytokines. 
Through a yet unknown mechanism, TLR8 additionally activates the NLRP3 inflammasome. This process yields 
to activation of caspase-1 which in turn processes pro-IL-1β into its active form. In contrast to canonical 
inflammasome activation, potassium efflux is not a feature of M. stadtmanae-induced inflammasome activation. 
(IL-1β, Interleukin 1β; IRF, Interferon regulatory factor; K+, Potassium ions; LDH, Lactate dehydrogenase; 
NF-κB, Nuclear factor ‘kappa-light-chain-enhancer’ of activated B cells; TLR, Toll-like receptor) 
In addition to TLRs, monocytes and DCs possess several intracellular nucleic acid-
specific receptors including RIG-I, MDA5 and cGAS (210). Although TLR8 was shown to be 
a key receptor in recognition of M. stadtmanae, an involvement of cytosolic receptors could not 
be excluded since translocation of other microbes and their nucleic acid from endo(lyso-)somes 
into the cytosol has been demonstrated (211-214). In VI.2.1 we showed that the cytoplasmic 
recognition pathways of RIG-I/MDA5-MAVS and cGAS-STING do not affect the response to 
M. stadtmanae. In absence of these pathways, neither secretion of pro-inflammatory cytokines 
nor the induction of IFN-β was significantly reduced. Moreover, the recently described process 
of STING-dependent NLRP3 inflammasome activation in human monocytes (38) was not 
involved as shown by the steady secretion of IL-1β from STING-/- cells after stimulation with 
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M. stadtmanae. We suggest that the recognition of M. stadtmanae is restricted to the 
endo(lyso-)somal compartment, at least for human monocytes. Involvement of cytosolic 
recognition pathways in other cell types or in in vivo models is still possible and needs to be 
evaluated. 
Even though TLR7 and TLR8 are both specific for ssRNA, our study shows a strong 
bias towards TLR8 in terms of cytokine secretion and IFN expression after stimulation with 
M. stadtmanae (chapter V). One possible explanation is that M. stadtmanae-derived RNA has 
a stronger affinity to TLR8 than to TLR7. Yet, it is more likely that a higher expression of 
TLR8 compared to TLR7 in human monocytes accounts for the stronger response through 
TLR8 (180). A recent study by Eng, et al. (215) supports our assumption that the TLR8 pathway 
is preferred by human monocytes and MΦ compared to the TLR7 pathway. To investigate the 
capability of TLR7 in recognition of M. stadtmanae RNA, another cell type with a higher TLR7 
expression such as plasmacytoid DCs (pDCs) (216, 217) could be used. Also, overexpression 
of TLR7 in BLaER1 monocytes is conceivable. Altogether, this study confirms that TLR7 and 
TLR8 are versatile receptors which are not restricted to recognize a single group of organisms 
but rather enable recognition of various microbes. For that reason, RNA can be considered as 
universal and conserved MAMP across all domains. 
3 M. stadtmanae activates a new inflammasome activation pathway 
In chapter V, we have demonstrated that M. stadtmanae induces secretion of IL-1β from 
primary and BLaER1 monocytes through activation of the NLRP3 inflammasome. The 
activation was shown to be dependent on all three inflammasome components, namely NLRP3, 
ASC, and caspase-1 and moreover dependent on TLR8 and MyD88 (Figure VII-1). This 
observation is consistent with the findings from Guo, et al. (187) who showed that TLR8-
dependent NLRP3 inflammasome activation through RNA from HIV in human monocytes is 
possible. Furthermore, the authors claimed that TLR8-mediated NLRP3 activation is dependent 
on CatB as they observed a decrease in IL-1β secretion using the CatB inhibitor CA-074 Me. 
We could not confirm these findings as BLaER1 CatB-/- monocytes still secreted solid amounts 
of IL-1β after stimulation with M. stadtmanae or R848 comparably to WT cells. Similar to our 
findings, Munoz-Planillo, et al. (47) showed that, although CA-074 Me inhibited IL-1β 
secretion from murine bone marrow-derived macrophages (BMDMs), cells from CatB-
deficient mice had no defects in NLRP3 activation. Off-target effects of CA-074 Me are most 
likely, which is supported by a study showing that CA-074 Me does not only inhibit CatB but 
also a wide range of different cathepsins (202). The authors mention that instead of CatB 
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cathepsin X (CatX) could be involved in NLRP3 activation (202). Therefore, the role of CatX 
in TLR8-mediated NLRP3 activation needs to be further determined. 
The alternative activation pathway has been described for human monocytes but is not 
present in murine cells. Its key characteristics are the secretion of IL-1β from living cells (no 
pyroptosis), independency of potassium efflux, and the absence of ASC specks (60). So far, the 
only known activator of alternative inflammasome activation is LPS. After binding of LPS to 
TLR4, the NLRP3 inflammasome is activated through a signal cascade initiated by TRIF and 
involving RIPK1, FADD, and caspase-8. In the case of M. stadtmanae- or R848-induced 
inflammasome activation, TRIF is dispensable as BLaER1 TRIF-/- were still able to secrete 
normal amounts of IL-1β, whereas LPS-stimulated cells did not. The exact mechanism of how 
TLR8 induces activation of the NLRP3 inflammasome remains elusive. While TRIF is 
negligible in TLR8-dependent inflammasome activation, an involvement of RIPK1, FADD, 
and caspase-8 cannot be ruled out. Both, TLR4- and TLR8-dependent inflammasome 
activation, show a delayed IL-1β secretion. In detail, canonical inflammasome activation 
through LPS/nigericin leads to high secretion of IL-1β already after four hours, whereas 
comparable amounts of IL-1β in alternative activation are detectable after about 18 hours. A 
similar delay was demonstrated after stimulation with M. stadtmanae in this study.  
The NLRP3 inflammasome activation induced by M. stadtmanae is distinct from 
canonical and non-canonical inflammasome activation. In detail, excessive cell death by 
pyroptosis and formation of ASC specks are key features of classical inflammasome activation 
pathways. Like LPS-mediated alternative inflammasome activation, M. stadtmanae does not 
induce ASC speck formation and only leads to cell death after comparatively long incubation 
times. Moreover, most canonical activation pathways can be inhibited by addition of high 
amounts of extracellular potassium as this blocks the mandatory efflux of cellular potassium 
(47, 59). Addition of potassium to the culture medium was shown to just have minor effects on 
M. stadtmanae-induced IL-1β secretion (VI.2.3). Although Gross, et al. (188) have shown that 
canonical inflammasome activation does not necessarily require potassium efflux, the TLR8-
mediated inflammasome activation by M. stadtmanae does rather reflect key features of the 
alternative inflammasome activation pathway (Table VII-1).  
Canonical inflammasome activation results in pyroptosis through pore formation of 
GSDMD on the inner cell membrane. GSDMD does not only cause lysis of eukaryotic cells but 
is also able to kill bacteria, which is thought as an additional mechanism of bacterial clearance 
in the cytosol of the host cell (54). In contrast to most other cytokines, IL-1β does not contain 
a signal leader peptide that results in secretion of the protein through the Golgi apparatus. 
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Instead, pro-IL-1β is formed in the cytosol where caspase-1 catalyzes its maturation. However, 
until GSDMD has been discovered, the molecular mechanism of how active IL-1β leaves the 
cell was unknown (218, 219). After GSDMD pores are formed, IL-1β is passively secreted 
through the pores. Yet, GSDMD pores do not necessarily induce pyroptosis as also living cells 
can form GSDMD pores through which IL-1β can leave the cell (55). It is unknown if GSDMD 
is also essential for IL-1β secretion after alternative inflammasome activation. Using 
GSDMD-/- BLaER1 monocytes, we demonstrated that neither alternative inflammasome 
activation through LPS nor M. stadtmanae-induced inflammasome activation are dependent on 
GSDMD as these KO cells are still able to secrete IL-1β. To our knowledge, no other IL-1β 
secretion mechanism besides GSDMD pore formation has been described. Identification of this 
alternative secretion mechanism is of great interest as it could serve as a new target to inhibit 
excessive and sterile inflammatory responses. 
 
Table VII-1. Key characteristics of different NLRP3 inflammasome activation pathways. 
 Canonical Alternative 
M. stadtmanae  
(TLR8) 
NLRP3 Yes Yes Yes 
ASC specks Yes No No 
Pyroptosis Yes No Yes* 
K+ efflux Yes No No** 
NEK7-
dependency 
Yes unknown largely 
GSDMD-
dependency 
Yes unknown No 
Species Human & Mouse Human only Human only 
Activators 
cellular stress, 
bacterial Toxins, 
crystals, … 
LPS → TLR4  
→ TRIF 
→ RIPK1/FADD 
/CASP8 
RNA → TLR8  
→ MyD88 
Overall, the TLR8-dependent inflammasome activation induced by M. stadtmanae 
exhibits important key features of alternative activation, which suggests that, in addition to 
* not for synthetic TLR8 ligands such as R848 
** only minor effects 
 
General Discussion 
83 
TLR4, TLR8 can also trigger a variation of the alternative NLRP3 inflammasome activation. 
Yet, the detailed molecular mechanism needs to be determined. Since TLR8 is located in 
endo(lyso-)somal compartments, it is possible that engagement of TLR8 induces leakage of 
lysosomal components into the cytosol. In various settings, lysosomal leakage was shown to 
trigger NLRP3 inflammasome activation (38, 200, 202). Other possible mechanisms include 
the formation of reactive oxygen species (ROS) (188, 220) or calcium ion (Ca2+) mobilization 
from the ER (221, 222). Further clarification is necessary, e.g. through usage of specific 
inhibitors or generation of KO cells targeting proteins involved in ROS generation or specific 
Ca2+ channels. 
4 Is RNA the only key to M. stadtmanae-mediated immune responses? 
Our study demonstrates that the methanogenic archaeon M. stadtmanae is recognized 
by its RNA through the endosomal receptors TLR7 and TLR8. However, in our setting myeloid 
immune cells are challenged with M. stadtmanae in an oxygenic environment, which does not 
reflect the situation in vivo since M. stadtmanae is strictly anaerobic (223). Though the archaeon 
has two genes encoding for oxygen detoxification proteins (224), it does not survive exposure 
to oxygen for a longer time. The actual effect of living archaea on immune cells or IECs has so 
far not been evaluated. Therefore, it cannot be completely ruled out that other mechanisms 
besides RNA recognition might play a role in the response induction against M. stadtmanae. It 
is possible that living cells of M. stadtmanae actively produce and secrete certain molecules like 
dinucleotides or peptides that could stimulate the immune system. Archaea also have the 
capability to secrete outer membrane vesicles (OMVs), which could deliver molecules or 
antigens that stimulate the innate or adaptive immune system (225). Yet, the role of OMVs in 
M. stadtmanae-induced immune cell activation is unclear. Moreover, some bacterial species 
can actively translocate from the lysosome into the cytosol (211). In this scenario, endosomal 
receptors are ineffective, while cytosolic receptors become important as they sense cytosolic 
pathogens. Whether archaea could actively overcome lysosomal degradation through 
translocation into the cytosol is also unknown. Furthermore, M. stadtmanae is able to form 
biofilms (226) and methanogenic archaea were shown to expresses surface glycans and 
adhesion-like proteins (95, 224). Bacteria in biofilms were shown to restrict their clearance 
through inhibition of phagocytosis and limitation of the immune response (227, 228). 
Therefore, biofilms can serve as an immune evasion strategy and significantly increase the 
virulence of pathogens. How biofilms influence the M. stadtmanae-induced immune responses 
is one of the key questions. 
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Besides the issue of how biofilms and living archaea alter the immune response, the role 
of archaeal lipids as stimulators of the innate and adaptive immune system also needs to be 
determined. Several studies have shown that liposomes derived from archaeal lipids, so-called 
archaeosomes, have a strong adjuvant activity (229, 230). Bacteria and eukaryotes utilize 
unbranched lipids species which are ester-linked to glycerol. In contrast, archaeal glycerol lipids 
are ether-linked and based on branched isoprenoid lipids (87). Several mechanisms of how 
archaeosomes provide an adjuvant function have been discussed (231) including the 
observation that archaeosomes show a much higher phagocytosis rate (3- to 53-fold) on murine 
peritoneal J774A.1 MΦs compared to conventional liposomes (232). This could be an 
explanation for the efficient phagocytic uptake of M. stadtmanae which has been described by 
Bang, et al. (114) and was also confirmed in this study (chapter IV). We suggest that the 
archaeal lipids are recognized by receptors on the surface of phagocytes like monocytes and 
DCs. These receptors might account for enhanced phagocytosis of M. stadtmanae, thus leading 
transportation of the archaea into the endo(lyso-)somes where the immune response is induced 
through engagement of TLR7 and TLR8. The just recently identified gut-associated archaeon 
M. luminyensis on the other hand exhibits only a low phagocytosis rate (chapter IV). Becker, et 
al. (233) have shown that M. luminyensis carries a unique lipid profile which is distinct from 
other methanogens. It has been proposed that the uptake of several archaeosomes is mediated 
through the phosphatidylserine receptor (234). Therefore, it is conceivable that M. luminyensis 
is inefficiently recognized by this (or a similar) receptor which leads to a decreased 
phagocytosis of M. luminyensis compared to M. stadtmanae. Archaeal lipids themselves might 
not necessarily serve as MAMPs but they could enhance the uptake of archaea which is directly 
linked to a TLR7/TLR8-mediated response as only phagocytosed archaea can be recognized. 
5 Is a disease-association of archaea possible? Consequences and future 
perspectives  
The question if archaea may function as pathogens, contribute to disease progression, 
or promote the growth of pathogenic bacteria through syntrophy has been discussed extensively 
(98, 203, 204, 235-240). Yet, a pathogenic archaeon has not been identified so far. This study 
is mainly focused on M. stadtmanae, a human gut inhabitant that appears to be associated with 
IBD (111) or lung hypersensitivity (113). M. stadtmanae is recognized through its RNA and 
induces strong secretion of inflammatory cytokines like TNF-α or IL-6. Moreover, we 
demonstrated that M. stadtmanae activates the NLRP3 inflammasome in TLR8-dependent 
pathway, while resembling key features of alternative inflammasome activation. This 
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observation is different from the other intestinal methanogenic archaea M. smithii (111, 114) 
and M. luminyensis (this study, chapter IV) which both only induce mild inflammatory 
responses. Blais-Lecours, et al. (111) recognized an increased prevalence of M. stadtmanae in 
IBD patients and elevated levels of antibodies against M. stadtmanae. On the other hand, IBD 
patients were found to have a decreased methane production (241) and lower loads of M. smithii 
(242). Based on these studies, M. stadtmanae may replaces M. smithii as the major intestinal 
methanogen in IBD patients (Figure VII-2). Thereby, M. stadtmanae could induce excessive 
immune response through its strong immunogenic activity and its potential to activate the 
NLRP3 inflammasome as demonstrated in this study. Additionally, replacement of M. smithii 
could alter the composition of the whole microbiota as many fermentative bacteria depend on 
syntrophy with this archaeon. In contrast, M. stadtmanae has different metabolic functions 
which could lead to dysbiosis of the microbiota. The keystone-pathogen hypothesis proposed 
by Hajishengallis, et al. (243) implies that certain low-abundance microorganisms, the so-called 
keystone-pathogens, could turn a healthy microbiota into dysbiosis, thereby promoting 
inflammatory diseases. Based on this hypothesis, M. stadtmanae could serve as such a 
keystone-pathogen and alter the composition of the microbiota through replacement of 
M. smithii. 
High exposure to bioaerosols in industrial animal farms can lead to pulmonary diseases 
such as farmer’s lung. It was shown that aerosols from dairy barns contain high amounts of 
M. smithii and M. stadtmanae (112) and furthermore, Bernatchez, et al. (113) demonstrated that 
aerosolized M. stadtmanae induces lung hypersensitivity in mice with symptoms resembling 
those of farmer’s lung. In contrast, M. smithii does not induce a strong inflammatory phenotype. 
In this setting, it is conceivable that M. stadtmanae may not act as a ‘classical’ pathogen but 
can cause inflammatory diseases through its high immunostimulatory activity. Our propagated 
model of M. stadtmanae-induced immune cell activation needs to be confirmed for this disease 
model. We have clearly demonstrated that M. stadtmanae induces activation of murine dendritic 
cells through mTLR7 as key receptor. Based on this observation, we assume that 
M. stadtmanae-induced lung hypersensitivity is TLR7-mediated. Therefore, it is necessary to 
use the same mouse model that was used in the study of Bernatchez, et al. (113) and compare 
the symptoms of WT and mTLR7-/- mice. If our assumption is correct, lung inflammation in 
TLR7-/- mice should become less severe as the innate immune system should not be activated. 
Overall, the role of archaea in human disease is still a mystery that must be solved. This 
is of clinical importance as treatment strategies of archaea-associated diseases must be 
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Figure VII-2. Hypothetic model of how M. stadtmanae contributes to IBD. 
(A) In healthy individuals, M. smithii is present in a relatively high abundance and promotes high diversity of the 
gut microbiota. The immune system and the microbiota homeostatic condition without induction excessive 
immune responses. (B) In IBD, the abundance of M. smithii is decreased, and (partially) replaced by M. stadtmanae 
which promotes alterations in the microbiota with reduced diversity and outgrowth of other, potentially harmful 
microbes (dysbiosis). The presence of certain microbes including M. stadtmanae leads to an increased influx of 
immune cells and excessive immune responses. (IBD, inflammatory bowel disease; IEC, intestinal epithelial cells) 
modified. Since archaeal cell walls and archaeal ribosomes are fundamentally different from 
those of bacteria, most antibiotics have no effect on archaeal growth and vitality (244). 
However, methanogenic archaea are susceptible to imidazole derivates (245) and lovastatins 
(246). This could be important for the treatment of periodontitis and brain abscesses where 
methanogenic archaea are most likely involved. For example, the use of metronidazole in brain 
abscesses has exceptionally improved its clinical outcome. There is a conceivable link between 
this drug and association of methanogens in this disease because metronidazole is one of the 
few antibiotics that is also effective against methanogenic archaea (110).To evaluate the disease 
association of archaea, archaea-specific detection methods should be routinely included in 
medical microbiology and in future microbiome studies.  
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IX Appendix 
1 TIDE analysis 
STING 
Clone TIDE analysis InDel 
B5 
 
+1/+2+4 
F9 
 
-1/+1 
G7 
 
+2/+7 
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RIG-I 
Clone TIDE analysis InDel 
B1 
 
+4/+4 
D8 
 
-26/-7 
E8 
 
+10/+13 
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MAVS 
Clone TIDE analysis InDel 
B1 
 
+1/+1 
C9 
 
-5/+1 
A11 
 
-5/-1 
 
CatB 
Clone TIDE analysis InDel 
B11 
 
-1/+1/ 
+4 
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GSDMD 
Clone TIDE analysis InDel 
A5 
 
+4/+10 
C6 
 
-1/+2/ 
+7 
H4 
 
-1/-1/+4 
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2 Figures 
 
Figure IX-1. Response to M. stadtmanae is independent of major cytosolic nucleic acid recognition pathways 
(all clones). 
(A) The expression of IFN-β in BLaER1 STING-/-, RIG-I-/- or MAVS-/- monocytes after stimulation with 
M. stadtmanae (100:1), 0.5 µg/ml 5’-ppp-RNA, or 1 µg/ml plasmid DNA for 6 h was measured by qRT PCR. The 
expression ratios of IFN-β gene to the reference gene HPRT are shown as log2 n-fold induction relative to the 
unstimulated control cells. (B) IL-1β and IL-6 secretion in the supernatants of BLaER1 WT, STING-/-, RIG-I-/- or 
MAVS-/- monocytes stimulated for 18 h with either 107 cells of M. stadtmanae, 107 cells/ml of L. lactis, 50 ng/ml 
LPS, or 5 µg/ml of R848. The data are shown as the mean ± SEM of three independent experiments (n=3) in (A) 
or four independent experiments (n=4) in (B). 
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Figure IX-2. Inflammasome activation and LDH release are independent of GSDMD (all clones). 
(A) IL-1β and IL-6 secretion and (B) release of LDH in the supernatants of BLaER1 WT or GSDMD-/- monocytes 
stimulated for 18 h with either 107 cells of M. stadtmanae, 5 µg/ml of CL097 5 µg/ml R848 or 50 ng/ml LPS. The 
data are shown as the mean ± SEM of four independent experiments (n=4). (GSDMD, gasdermin D; IL-1β, 
interleukin 1 beta; IL-6, interleukin 6; LDH, lactate dehydrogenase; nig, nigericin) 
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